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ABSTRACT 
Oxidative stress and mitochondrial dysfunction have major roles in the 
pathophysiology of cardiovascular disease. Mitochondria are the predominant source of 
energy production in the heart. Mitochondrial dysfunction decreases ATP production, 
while increasing reactive oxygen species (ROS) production. Early mitochondrial 
dysfunction leads to a vicious cycle, where excess ROS damages the mitochondria, leading 
to increased ROS production and impaired ATP production, decreasing the heart’s 
energetic capacity. Therefore, targeted mitochondrial antioxidants are a promising 
therapeutic target for cardiovascular disease and identification of novel endogenous 
mitochondrial antioxidants could lead to the discovery of new therapeutic targets.  
 ABCB10 is a mitochondrial transporter with an unknown substrate. Our laboratory 
showed that hearts from mice with a heterozygous deletion of ABCB10 had decreased 
cardiac function and increased oxidative stress after ischemia reperfusion. Administration 
of an antioxidant ameliorated these effects, indicating that ABCB10 may have antioxidant 
effects. Therefore, we hypothesize that ABCB10 protects cardiac myocytes against 
oxidative injury through antioxidant effects in the cytosol and/or mitochondria. To test this 
hypothesis, we overexpressed ABCB10 in isolated adult rat ventricular myocytes 
 
 ix 
(ARVMs) and exposed these cells to an oxidative challenge. ABCB10 overexpression 
protected cardiac myocytes against an oxidative insult, increasing cell viability and 
decreasing cytosolic ROS levels. ABCB10 overexpression also increased levels of HO-1, 
a cardioprotective and antioxidant-generating enzyme.  
We generated cardiac-specific ABCB10 knockout mice to explore the role of 
cardiac ABCB10 in vivo. We found that cardiac-specific deletion of ABCB10 in mice 
caused early death and mitochondrial dysfunction, evidenced by increased mitochondrial 
ROS production and decreased mitochondrial oxygen consumption. Additionally, 
microarray gene analysis revealed that hearts from ABCB10 knockout mice downregulated 
mitochondrial transcription and translation processes, indicating impaired mitochondrial 
proteostasis. These findings demonstrate that ABCB10 exerts an antioxidant effect, due, at 
least in part, to upregulation of the HO-1 antioxidant system. The ABCB10 mitochondrial 
transporter is involved in regulating mitochondrial oxidant levels and proteostasis and may 
be a novel therapeutic target in states associated with oxidative stress.  
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CHAPTER ONE: Introduction 
Heart Failure and Oxidative Stress 
 Cardiovascular disease is the leading cause of death globally and is expected to 
cause more than 22 million deaths by 2030 1. As the population ages, heart failure 
prevalence is only expected to increase. Oxidative stress and mitochondrial dysfunction 
are major drivers of heart disease 2–5. Failing hearts generate increased reactive oxygen 
species (ROS), as reflected by increased markers of oxidative stress 6–10. The predominant 
source of ROS in the failing heart is dysfunctional mitochondria 11–13. The heart has 
incredibly high energy demands. It accounts for 8% of daily ATP consumption, even 
though it only accounts for approximately 0.5% of body weight in humans 14. The heart 
relies on mitochondrial respiration to produce more than 90% of the heart’s energy 15. 
Approximately 30% of the cardiac myocyte’s space is devoted to mitochondria 15,16.  
Mitochondrial dysfunction often precedes cardiac dysfunction in in vivo models of 
heart failure 5,17,18. Mitochondria produce ROS as a byproduct of electron transport, 
predominantly through complex I, complex III, and at sites linked to the NADH or CoQ 
pools 19. Under physiologic conditions, mitochondria produce very little ROS, which is 
scavenged by endogenous antioxidant systems 3,19. However, under conditions of stress, 
such as ischemia or excess nutrients, mitochondrial ROS production increases and ROS 
scavenging capacity decreases 20. Early mitochondrial dysfunction leads to a vicious cycle, 
where excess ROS damages the mitochondria, further increasing ROS production, 
impairing ATP production, and decreasing the hearts energetic capacity 4. Mitochondria 




and oxidatively-modified proteins 24,25. ROS-induced mitochondrial DNA release can 
trigger the inflammatory response 4,26. Excess ROS can also cause the mitochondrial 
permeability transition pore (mPTP) to open, inducing a massive release of ROS, and 
ultimately cell death 27. Furthermore, ROS from the mitochondria travel throughout the 
myocyte, oxidizing proteins and lipids, and ultimately impairing contractile function and 
inducing apoptosis (figure 1.1) 4,22.  
 
Figure 1.1: Cellular Effects of Mitochondrial ROS. Mitochondria produce reactive 
oxygen species (ROS) through the respiratory chain. Under pathological conditions, this 
excess ROS can cause mutations in mitochondrial DNA (mtDNA), further impairing 
mitochondrial function. Mitochondrial oxidative damage can also induce cytochrome C 
(cyt C) release by mitochondrial outer membrane permeabilization (MOMP) and opening 
of the mitochondrial permeability transition pore (PTP), both leading to apoptosis. From 




 There are no current antioxidant therapies for humans. Vitamin E treatment did not 
improve outcomes for patients at high risk of cardiovascular events 28.  Administration of 
a ROS scavenger only provided modest benefits for patients with acute myocardial 
infarction 29. The antioxidant therapies that have been tested in humans do have flaws. 
These therapies have poor tissue permeability, ineffective doses, and importantly were not 
targeted within the cell 14. Physiologic ROS production is an important part of adaptive 
cellular signaling within the cardiac myocyte 30. Antioxidant supplementation may reduce 
the beneficial effects of exercise, indicating that modest increases in ROS can have 
beneficial effects 31. Numerous studies have suggested that reducing mitochondrial ROS 
can preserve mitochondrial function and protect against heart failure 14,32,33. One of the 
most promising antioxidant therapies is CoQ10, a potent lipid-soluble antioxidant and 
essential component of the electron transport chain. Treatment with CoQ10 reduced 
cardiovascular mortality, all-cause mortality, and hospital stays for patients with moderate 
to severe heart failure 34.  Targeting antioxidants to the mitochondria, where pathologic 
ROS production occurs during disease, may provide therapeutic benefit, without impairing 
basal ROS signaling.  
 Multiple groups have tested the therapeutic potential of mitochondrial-targeted 
antioxidants, using both transgenic approaches and pharmacological intervention. 
Overexpression of catalase within mitochondria protected against myocardial dysfunction 
and failure in murine models of metabolic heart disease 35 and aging 36. Administration of 
MitoQ, a targeted mitochondrial antioxidant, protected against oxidative stress and 




restored mitochondrial respiration, improved lung congestion, and reduced right 
ventricular hypertrophy in a murine pressure overload model 38.  Superoxide dismutase 
mimetics reduced cardiac dysfunction and mitochondrial ROS production in rodent models 
of dilated cardiomyopathy 39, pressure overload 40,41, and ischemia/reperfusion 42. These 
studies demonstrate the therapeutic potential of targeted mitochondrial antioxidants and 
further, suggest that the identification of novel mitochondrial antioxidant pathways could 
lead to the development of potential therapeutic targets.  
ABCB10   
ABCB10 and Heme 
ATP-Binding Cassette Protein 10 (ABCB10) is a mitochondrial transporter of an 
unknown substrate. ABCB10 (originally called ABC-me) was discovered in the inner 
mitochondrial membrane of erythroid cells twenty years ago 43. Shortly thereafter, 
ABCB10 was identified in humans (named M-ABC2) as a mitochondrial protein expressed 
in tissues throughout the body, with highest expression levels in bone marrow and 
intermediate to  high expression in heart, skeletal muscle, small intestine, brain, liver, 
pancreas, and thyroid 44. Later studies confirmed that ABCB10 contains an unusually long 
mitochondrial targeting sequence and that ABCB10 homodimers localize to the 
mitochondrial inner membrane 45. Shirihai et al showed that ABCB10 is highly induced by 
GATA-1 during erythropoiesis 43. GATA-1 is a transcription factor that regulates many 
erythroid-expressed genes, including genes associated with heme biosynthesis 43. Since 
ABCB10 is closely tied with heme synthesis, it makes sense that ABCB10 would also be 




overexpression increases hemoglobin production 46. Whole body ABCB10 knockout mice 
die at day 12.5 of gestation, due to a lack of erythropoiesis 46,47. ABCB10 -/- blood cells 
had higher levels of apoptosis, increased oxidative stress, and increased mitochondrial 
reactive oxygen species production 46.  Furthermore, hematopoietic cells lacking ABCB10 
have decreased heme biosynthesis, accumulate protoporphyrin IX and iron within the 
mitochondria, and have impaired maturation 47. These studies all demonstrate that 
ABCB10 is necessary for normal heme biosynthesis and has obvious physiological 
significance; however, the question remains what role exactly does ABCB10 have in 
regulating heme synthesis?  
 Many groups have worked to answer this question and two hypotheses have 
emerged. One hypothesis is that ABCB10 affects the early stages of heme synthesis, 
possibly by exporting δ-aminolevulinic acid (ALA). The other hypothesis is that ABCB10 
affects the late stages of heme synthesis, specifically iron utilization. I will review the data 
supporting and contradicting both hypotheses here, but first I will give a brief overview of 
the steps of heme synthesis (figure 1.2). First, succinyl CoA and glycine are converted to 
aminolevulinic acid (ALA) by ALA synthase in the mitochondria 48. ALA is then exported 
to the cytosol, where it undergoes a variety of reactions, ultimately forming 
coproporphyrinogen III 48. Coproporphyrinogen III is transported back into the 
mitochondria, where it is converted to protoporphyrinogen IX by coproporphyrinogen 
oxidase 48. Protoporphyrinogen oxidase then oxidizes protoporphyrinogen IX to 
protoporphyrin IX (PPIX) 48. Finally, iron is incorporated into PPIX by ferrochelatase 





Figure 1.2: Heme Synthesis Pathway. Reprinted with permission from Ryter et al.  Free 
Radical Biology and Medicine 2000  
The first studies linking ABCB10 with regulation of early steps of heme synthesis 




reduced heme content and porphyrin levels. They also showed that addition of ALA could 
restore the heme content 49. Overexpression of ALA synthase 2 did not rescue heme levels 
in the ABCB10 knockdown cells. Since ALA synthase 2 generates ALA within the 
mitochondria, these findings indicated that ABCB10 may export ALA into the cytosol, 
facilitating the early stages of heme synthesis. However, further studies demonstrated that 
ALA does not stimulate the ATPase activity of ABCB10 50 and that ALA is still exported 
from mitochondria in ABCB10-null cells 51, ruling out ALA as a possible substrate of 
ABCB10. Seguin et al did find that ALA synthase 2 activity was reduced in ABCB10 
knockdown cells, possibly explaining the rescuing effects of ALA in the earlier studies 51. 
Interesting, Seguin et al also found that silencing ABCB10 led to a decrease in 
mitochondrial and cytosolic heme biosynthesis genes in both undifferentiated and 
differentiated ABCB10-null mouse erythroleukemia cells 51. They found that silencing 
ABCB10 increased the activity of the transcriptional repressor Bach1, although protein 
levels of Bach1 were unchanged 51. Bach1 is regulated by heme and regulates genes 
associated with heme synthesis and oxidation, as well as oxidative stress.  Finally, Seguin 
et al showed that the ATP-hydrolysis activity of ABCB10 is necessary for 
hemoglobinization, indicating that ABCB10’s substrate may play a role in regulating heme 
synthesis, possibly by affecting transcription of enzymes involved 52. While it has been 
shown that ABCB10 does not export ALA, it is possible that ABCB10 can regulate the 





 The second hypothesis for how ABCB10 regulates heme synthesis proposes that 
ABCB10 affects iron utilization by acting as a scaffolding protein for mitoferrin-1 and 
ferrochelatase. Chen et al showed that ABCB10 binds to and stabilizes mitoferrin-1, the 
main iron importer in mitochondria 53. Mitoferrin-1 is essential for heme synthesis, since 
iron must be imported to the mitochondria to be incorporated into protoporphyrin IX to 
form heme. Lower mitoferrin-1 levels would reduce iron import into the mitochondria, 
decreasing the amount of iron available for heme biosynthesis. This same group also 
showed that ABCB10 and mitoferrin-1 form a complex with ferrochelatase (FECH), the 
final enzyme in heme synthesis 54. FECH catalyzes the insertion of iron in protoporphyrin 
IX, forming heme. Maio et al confirmed this finding, showing that ABCB10 binds to FECH 
which also interacts ABCB7 55. Taken together, these studies demonstrate that ABCB10, 
mitoferrin-1, and FECH form a complex that is necessary for both iron import into the 
mitochondria and iron insertion into heme. Disruptions in ABCB10 would disturb this 
complex, impairing iron utilization and reducing heme synthesis. In fact, ABCB10 null 
blood cells accumulated protoporphyrin IX and iron, supporting the hypothesis that 
ABCB10 regulates the function of FECH and mitoferrin-1 47. However, there are many 
studies that conflict with this hypothesis. Bayeva et al found that porphryins, the precursors 
to PPIX, accumulated in ABCB10 knockdown cardiac myoblasts 49. If ABCB10’s main 
function was to facilitate the import and insertion of iron into PPIX, then PPIX should 
accumulate in ABCB10 knockout cells, not its precursors. Furthermore, zebrafish lacking 
ABCB10 do not accumulate intermediate porphyrins or PPIX 51. Mouse erythroleukemia 




accumulate PPIX 52. While it is clear that ABCB10 can bind to mitoferrin-1 and FECH, 
the significance of this interaction seems to vary depending on cell type and the model 
system.  
 The recent identification of a possible mitochondrial heme metabolism protein 
complex shows that all mitochondrial steps of heme synthesis are closely tied 56. This 
complex is made up of proteins associated with almost every mitochondrial step of heme 
synthesis including ABCB10, FECH, mitoferrin-1, ALAS2, and protoporphyrinogen 
oxidase (figure 1.3). If ABCB10 acts as a scaffolding protein for the mitochondrial heme 
metabolism protein complex, then ABCB10 deletion could disrupt the complex. An 
impaired mitochondrial heme metabolism protein complex could lead to reduced FECH 
activity, reduced ALAS2 activity, impaired iron utilization, accumulation of intermediate 
porphyrins, and ultimately impaired heme synthesis. The mitochondrial heme metabolism 
protein complex ties together the early and late stages of heme synthesis and could explain 
the discrepancies concerning ABCB10’s regulation of heme synthesis.  
The crystal structure of ABCB10 has been solved and provides some insights into 
its possible functions. The nucleotide binding domains of ABC transporters, including 
ABCB10, are highly conserved across species and proteins 57. There are exposed patches 
on the inner membrane of ABCB10 that are conserved across paralogues in 80 species and 
may represent a substrate binding domain for an amphipathic molecule 57. The outer 
membrane of ABCB10, where protein-protein interactions would occur, is not conserved, 
indicating that ABCB10’s conserved function is related to substrate transport rather than 




mitochondrial heme metabolism protein complex, specifically binding to and stabilizing 
mitoferrin-1 and ferrochelatase; however, ABCB10’s primary function is to export its 
unidentified substrate.  
 
Figure 1.3: Putative Mitochondrial Heme Metabolism Protein Complex. IMM refers 
to the inner mitochondrial membrane. OMM refers to the outer mitochondrial membrane. 
EN refers to the endosome. From Medlock et al. PLoS One 2015 
ABCB10 as a Possible Antioxidant 
Many groups have hypothesized that ABCB10 functions as an antioxidant, due to 
its regulation of heme. Heme is a reactive and potentially toxic molecule that can produce 
free radicals through the Fenton reaction 58. Free heme oxidizes lipid membranes 59,60, 
increases endothelial cells susceptibility to oxidative insult 61, damages genomic and 




and increases ER stress 65. Heme is a necessary cofactor for many proteins, including 
cytochrome c, hemoglobin/myoglobin, catalase, guanylyl cyclase, and NOS proteins 66.  
Under normal conditions, free heme is inserted as a prosthetic group into various 
hemoproteins, buffering its toxic effects 66,67. However, oxidative stress can induce 
hemoproteins to release free heme, furthering increasing oxidant levels 66.  
 Heme degradation via heme-oxygenase 1 is one of the main tools cells use to limit 
heme toxicity. HO-1 is an inducible protein that oxidizes heme to iron, carbon monoxide 
(CO), and biliverdin 68,69. CO has been shown to protect against apoptosis and 
inflammation 70,71. Biliverdin is rapidly converted to the antioxidant bilirubin by biliverdin 
reductase 72,73. Heme can induce HO-1 expression by binding to Bach1, a transcriptional 
repressor that can bind to enhancer elements in HO-1’s promoter 66,74. Once Bach1 is 
released from HO-1’s promoter, then Nrf2 is free to bind the enhancer elements and 
upregulate HO-1 74. These studies demonstrate that both free heme and heme degradation 
regulate the redox status of the cell. By modifying heme levels, ABCB10 could act as an 
antioxidant. If ABCB10 activation increases heme levels, it could induce HO-1 
upregulation and increase the cell’s antioxidant capacity. Similarly, if ABCB10 inhibition 
reduces heme levels, it could reduce the activity of hemoproteins, like catalase, and prevent 
the cell from activating HO-1 in response to stress.  
 Multiple studies have shown that ABCB10 can, in fact, regulate oxidative stress in 
a variety of cell types. Erythroid precursors lacking ABCB10 have increased mitochondrial 
ROS production and increased protein carbonylation, a marker of oxidative stress 46. 




ABCB10-null erythroid precursors, further indicating that ABCB10 deletion caused 
oxidative stress 46. Liver cells lacking ABCB10 have increased mitochondrial ROS 
production and increased protein carbonylation 47. ABCB10 deletion increased 
mitochondrial ROS production in striatal cells and ABCB10 overexpression reduced 
mitochondrial ROS production in a Huntingtin’s disease cell model 75. Hearts with 
heterozygous deletion of ABCB10 had increased oxidative stress after 
ischemia/reperfusion 76. Additionally, ABCB10 appears to be regulated by Nrf2, which 
regulates the expression of many antioxidant genes 77. Nrf2 silencing in a blood brain 
barrier cell line led to decreased ABCB10 expression and pharmacological activation of 
Nrf2 increased ABCB10 expression 77. ABCB10 clearly has a role in regulating oxidative 
stress, possibly by affecting heme levels. It is likely that ABCB10 has therapeutic potential 
for disease states driven by oxidative stress and ROS production, including cardiovascular 
disease. Further studies are needed to understand the mechanism of ABCB10’s antioxidant 
function. 
ABCB10 and UPR 
ABCB10’s orthologues in other species, specifically yeast and C. Elegans, can 
inform us about possible functions of mammalian ABCB10. ABCB10 shares 43% identity 
(78% sequence coverage) with the yeast protein multidrug resistance like 1 (MDL1) and 
44% identity (79% sequence coverage) with the C. Elegans protein Haf-3 78. MDL1 exports 
peptides, which have been digested by the matrix AAA protease, from isolated 
mitochondria 79. The molecular function of Haf-3 is unknown, but its homologue, Haf-1, 




related to ABCB10 (share 40% identity and 77% sequence coverage) and is necessary for 
activating the mitochondrial UPR 80. C. Elegans lacking Haf-1 accumulate peptides within 
the mitochondria, impairing the mitochondrial unfolded protein response, and reducing 
mitochondrial oxygen consumption 80. Mitochondrial peptide export could serve two 
functions: 1) to protect the mitochondria from accumulation of toxic peptide aggregates or 
2) to signal to the rest of the cell that the mitochondria are undergoing stress.  
 Based on the functions of Mdl1 and Haf-1, it was thought that ABCB10 may also 
export peptides from the mitochondria. In 2017, Yano showed that knocking down 
ABCB10 in liver cells did not inhibit mitochondrial peptide export, demonstrating that 
ABCB10 does not export peptides 81. However, data shows that ABCB10 does regulate the 
mitochondrial unfolded protein response (UPRmt) through an alternative mechanism. 
Yano observed in the previous study that ABCB10 knockdown reduced the expression of 
various mitochondrial chaperones and proteases (LONP1, HSPD1, DNAJA3), but did not 
affect the expression of endoplasmic proteins (calnexin and HSP90B1) 82. Another study, 
in a murine model of depression, showed that ABCB10 was upregulated along with other 
markers of UPRmt (Clpp, Hspa9, Hsp60, and Ubl5) 83. ABCB10 depletion in striatal cells 
reduces expression of both the mitochondrial chaperone HSP60 and the mitochondrial 
protease Clpp 75. Additionally, they showed that ABCB10 regulates CHOP, a transcription 
factor that regulates UPR-associated genes including HSP60 and Clpp 75. ABCB10 
overexpression increased CHOP levels and ABCB10 knockdown reduced CHOP levels 75. 
These studies demonstrate that ABCB10 regulates mitochondrial UPR through an 




 It is possible that ABCB10’s regulation of UPR could be associated with its 
regulation of heme content. Increased free heme can induce ER stress in human aortic 
smooth muscle cells, increasing levels of ATF4, p-eiF2α, CHOP, and GRP78 65. When 
heme binding proteins were present, this effect was inhibited, showing that free heme can 
cause ER stress and activate UPR 65. Heme-induced ER stress was also inhibited by an 
antioxidant, indicating that heme induces ER stress by oxidatively modifying proteins 65. 
Additionally, bilirubin, a product of heme degradation by HO-1, can increase levels of 
various markers of ER stress (Xbp1, GRP78, CHOP, and Il6) in hepatocytes 84. Since 
ABCB10 can affect levels of heme, and consequently levels of ROS, it is possible that 
ABCB10’s effect on UPR signaling is merely a downstream consequence of altered heme 
or ROS levels. ABCB10 knockdown reduces heme levels and lower free heme levels 
reduce levels of CHOP 85, which could explain the finding that decreasing ABCB10 
reduces CHOP levels.  
Decreasing ABCB10 increases mitochondrial ROS production and causes 
oxidative stress 75,76. ROS can damage mitochondria and oxidize proteins, activating 
UPRmt 86. Therefore, if ABCB10’s effect on UPR was completely mediated by ROS, then 
ABCB10 knockdown should increase levels of UPRmt genes. Rather the opposite is true. 
ABCB10 knockdown impairs UPRmt, reducing levels of key chaperones and proteases 
75,82. These findings indicate that ABCB10 regulates UPRmt through a mechanism 
secondary to ROS. It is possible that ABCB10’s substrate, which remains unidentified, 
could act as a signal of mitochondrial health and proteostasis to the rest of the cell. If this 




mitochondria and inhibit expression of UPRmt genes. More studies are needed to 
determine the exact relationship between ABCB10 and UPRmt, but it is clear that the two 
are closely tied.  
ABCB10 in the Heart 
The heart has an incredibly high ATP demand and consequently cardiac myocytes 
are loaded with mitochondria to support their energy demands for contraction 16,87. Due to 
its high levels of mitochondria and high rates of oxygen consumption, the heart is 
susceptible to oxidative injury. As mentioned earlier, oxidative stress has been implicated 
in the pathophysiology of various cardiovascular diseases including ischemia/reperfusion, 
aging, metabolic heart disease, and pressure overload 35–37,88–92. Additionally, the heme 
oxygenase antioxidant system is necessary to protect the heart against ischemia/reperfusion 
70,93–95. Therefore, novel cardiac antioxidants are promising therapeutic targets for 
cardiovascular disease.  
ABCB10 is abundantly expressed in the heart 44. Hearts from whole body 
heterozygous ABCB10 knockout mice do not have altered function basally 76. ABCB10 
+/- hearts have normal mitochondrial function and no signs of oxidative stress at baseline 
76. However, ABCB10 +/- hearts are more susceptible to ischemia/reperfusion. Hearts from 
whole body heterozygous ABCB10 knockout mice had increased markers of oxidative 
stress, decreased ATP content, and impaired cardiac recovery after ischemia/reperfusion 
76. Antioxidant administration ameliorated this phenotype, indicating that ABCB10 plays 
an antioxidant role in the heart. Unfortunately, since these studies were conducted in hearts 




determine if ABCB10 has an antioxidant action in the cardiac myocyte specifically, or if 
its protective effect occurred in the other cell types of the heart.  
 Our hypothesis that ABCB10 has an antioxidant function in the heart is supported 
by another study conducted in cardiac myoblasts 49. The investigators showed that 
ABCB10 is upregulated in hypoxic H9c2 cells 49. When ABCB10 upregulation was 
inhibited in hypoxic cardiac myoblasts, mitochondrial ROS production and cell death 
increased, demonstrating that ABCB10 may have a cardioprotective role. When ABCB10 
was reduced in paced neonatal rat myocytes, the cells had a significant increase in the delay 
time, a marker of calcium removal 49. ABCB10 knockdown reduced the protein level of 
the sodium calcium exchanger, which could explain the impairment in calcium reuptake. 
We have also shown that SERCA can be oxidatively modified and inhibited during 
oxidative stress 96,97. By increasing ROS levels, ABCB10 knockdown could lead to 
SERCA oxidation and inhibition, impairing calcium reuptake after contraction and 
increasing the delay time. Additionally, they found that ABCB10 is upregulated in hearts 
of mice exposed to myocardial infarction and that ABCB10 is upregulated in cardiac 
explant samples from ischemic cardiomyopathy patients 49. ABCB10 is also upregulated 
in the hearts of aged rats 98. ABCB10 clearly has a significant role in the heart, particularly 
during times of oxidative stress; however, ABCB10’s exact function in the heart remains 
to be determined.  
If ABCB10 acts as an antioxidant in the heart, it could have great therapeutic 
potential for a variety of cardiovascular diseases. However, more studies are needed to 




down ABCB10 impairs cardiac myocyte function after a stressor; however, it remains to 
be determined if increasing ABCB10’s activity can actually protect the cardiac myocyte 




















Hypothesis and Specific Aims 
Hypothesis 
Hypothesis: ABCB10 protects cardiac myocytes against oxidative injury through 
antioxidant effects in the cytosol and mitochondria. 
Specific Aims 
Aim 1. Investigate the role of ABCB10 in vitro in regulating the cardiac myocyte’s 
response to an oxidative challenge.  
 To test this hypothesis, we overexpressed ABCB10 in isolated adult rat ventricular 
myocytes (ARVMs) and exposed those cells to an oxidative challenge. We then measured 
cytosolic ROS levels, cell survival, and heme levels in ABCB10 ARVMs to determine if 
ABCB10 overexpression protected against an oxidative challenge.  
 
Aim 2. Investigate the role of ABCB10 in regulating mitochondrial and cardiac 
function in vivo  
To test this hypothesis, we generated a cardiac myocyte specific ABCB10 knockout 
mouse. We measured mitochondrial function, cardiac function, survival, and differential 
gene expression to determine if ABCB10 is necessary to maintain mitochondrial and 








CHAPTER TWO: Materials and Methods 
Methods for Chapter Three 
Cardiomyocyte Isolation and Culture 
Adult rat ventricular myocytes (ARVMs) were isolated from the hearts of adult 
male Sprague-Dawley rats (175-200 g, Harlan) as we previously described 99  and cultured 
in serum-free media. In brief, hearts were excised and retrograde perfused with Ca2+ free 
Krebs-Henseleit Buffer (KH: 118 mM NaCl, 4.75 mM KCl, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 25 mM NaHCO3, 48 mM dextrose, pH 7.4) at a rate of 7.5-8 mL/min for 2 
minutes through the aorta at 37 °C.  The heart was then digested with a recirculating KH 
solution containing collagenase type II (0.14-0.15 mg/mL, Sigma) and hyaluronidase Type 
II (0.14-0.15 mg/ML, Sigma) for 17 minutes. Hearts were then halved, quartered, and 
minced into longitudinal strips. Cells from the left ventricle were released by shaking the 
tissue at 37°C in KH digestion buffer supplemented with DNAse (0.02 mg/mL, 
Worthington), Trypsin Type IX (0.02 mg/mL, Sigma), and 1 mM CaCl2 for 25 minutes and 
then centrifuged for 3 minutes at 50 x g. The cells were filtered through a 100-µM mesh 
filter and allowed to settle for 10 minutes in wash buffer (50% KH, 50% DMEM). The 
cells were resuspended in DMEM (Gibco), layered over 0.0645g/mL BSA (Sigma) to 
separate ventricular myocytes from nonmyocytes, and allowed to settle again for 10 
minutes. The cells were then resuspended in ACCT medium consisting of DMEM 
containing 0.2% BSA (Sigma), 2 mM L-carnitine (Sigma), 5 mM creatine (Sigma), 5 mM 
taurine (Sigma), 2.5 M HEPES and 100 U/mL penicillin-streptomycin (Gibco). The 




mm glass bottom culture dishes (MatTek) precoated with laminin (10 µg/mL Invitrogen). 
After 1 hour, the ARVMs were washed with ACCT to remove unattached cells. After 48-
72 hours in culture, ARVMs were treated with 500 µM H2O2 for 10 minutes for oxidative 
challenge assays. 
Adenoviral Constructs and ARVM Infection 
Adenoviral constructs encoding ABCB10 49, HyPer 100,101, and Perceval-HR 102 
were constructed as we previously described 103. The ABCB10 adenovirus was graciously 
provided by Dr. Marc Liesa, University of California Los Angeles. The ABCB10 
adenovirus was propagated in HEK-293 cells and purified using a double cesium chloride 
gradient to remove noninfectious empty capsids 104. The HyPer and mitoHyPer constructs 
were obtained from Evrogen. Perceval-HR constructs were obtained from Addgene. The 
inserts of HyPer, mitoHyPer, and Perceval-HR were excised from pcDNA3.1 and ligated 
into EcoRV site of pShuttle, under the cytomegalovirus promoter. The shuttle vector was 
transfected in E. Coli with pADEasy. The appropriate cosmids were removed by PAC-1 
digestion and transfected into HEK-293 cells using calcium phosphate. The adenoviruses 
were propagated in HEK-293 cells and purified using a double cesium chloride gradient. 
ARVMs were infected with ABCB10 equivalent to approximately a 40-fold 
overexpression vs endogenous ABCB10 (n=4, p<0.05) for 36 hours (figure 2.1). An 
adenovirus encoding β-galactosidase (LacZ) was used as a control for all experiments, as 
we previously described 105. Uniformity of expression was not assessed for HyPer, 






Figure 2.1. ABCB10 Overexpression in ARVMs. Western blot analysis of ABCB10 
levels in LacZ and ABCB10 ARVMs. All samples were normalized to GAPDH (n=4, 
p<0.01)  
Cell Survival Assay 
Cell viability was measured by Trypan Blue uptake as we previously described 106. 
Briefly, cells were washed in PBS and then incubated with Trypan Blue diluted with equal 
parts PBS for 5 minutes. Cells were washed with PBS again and then the percentage of 
nonviable trypan-blue positive cells was determined by randomly counting 300 cells in 
each plate.  
Cellular Imaging 
ARVMs were transfected for 72 hours with an adenovirus encoding HyPer 100,107, 




the ATP:ADP fluorescent probe 102. Cells were imaged at 37° using an inverted Olympus 
Spinning Disk confocal microscope in wide field mode as previously described 103. All 
optical filters were purchased from Chroma: excitation 390/70 nm, GFP 470/510 nm, and 
emission EGFP(FITC/Cy2). Cells were excited at 390 and 480 nm and emission was 
collected with a rapid emission filter changer. For HyPer studies, cells were imaged every 
15 seconds for 10 minutes. For Perceval, cells were imaged every 30 seconds for 5 minutes. 
Ratiometric images were calculated after background subtraction by dividing GFP-excited 
images over 390 excited images. Images were analyzed using the NIS Elements software 
(Nikon). Only rod-shaped cells were used for this analysis.  
Adenoviral RNA Isolation and RT-PCR Analysis 
Total RNA was extracted from ARVMs and frozen left ventricle using the RNeasy 
Plus Mini Kit (Qiagen). Total RNA was treated with DNAse and cDNA was synthesized 
using the High Capacity RNA-to-cDNA Kit (Applied Biosystems) as we previously 
described 108. Quantitative PCR was performed with TaqMan Universal PCR Master Mix 
and TaqMan primers (Applied Biosystems) specific for sirtuin1 (Rn01428096), Nrf2 
(Rn00582415), catalase (Mn00437992), super oxide dismutase 1 (Rn00566938), super 
oxide dismutase 2 (Rn00690588), heme oxygenase 1 (Rn00561387), biliverdin reductase 







Protein Dilution Company 
ABCB10 1:1000 Abcam 
HO-1 1:1000 Abcam 
VDAC 1:1000 Abcam 
AMPK (total) 1:1000 Cell Signaling 
pAMPK172 1:1000 Cell Signaling 
CHOP 1:1000 Cell Signaling 
ATF4 1:1000 Cell Signaling 
Electron Transport Chain Cocktail 1:1000 Abcam 
GAPDH 1:5000 Abcam 
Table 2.1. Antibodies used for Western Blot Analysis 
Western Blot Analysis  
Cells were rinsed with PBS, lysed in 2% SDS lysis buffer (2% SDS and 5 mM 
EDTA) needle-lysed with a 31½-gauge insulin needle to shear DNA. Protein concentration 
was calculated using BCA (Pierce). Lysates were boiled for 5 minutes at 95°C.  Proteins 
(20-30 ug) were separated by SDS-PAGE on polyacrylamide gels and transferred to 
Immobilon-FL PVDF membranes (Millipore). The proteins were then blocked with Licor 
Odyssey Blocking Buffer (Licor) for 1 hour at room temperature, then incubated with 
primary antibodies outlined in table 2.1 at 4°C overnight. Proteins were detected with 
IRDye® 680RD goat (polyclonal) anti-mouse IgG (H + L) or 800CW donkey (polyclonal) 
anti-rabbit IgG (H + L) infrared (IR) conjugated secondary antibodies (Licor).  




Methods for Chapter Four 
Experimental Animals 
Cardiomyocyte-specific ABCB10 knockout mice were generated by crossing 
ABCB10 +/- mice 47 with αMHCCre mice (alpha myosin heavy chain-driven Cre 
recombinase) (Jackson Laboratory, Bar Harbor, ME). ABCB10 knockout was confirmed 
with qRT-PCR (figure 2.2). Cardiomyocyte ABCB10 -/- mice (ABCB10 flox/flox, Cre/+) 
were compared with both WT flox/flox controls and WT Cre+ controls. The institutional 
animal care and use committee of Boston University School of Medicine approved all 
animal experiments and all experiments were in accordance with institutional guidelines. 
 
Figure 2.2. ABCB10 mRNA is significantly reduced in CM-ABCB10 -/- mice. qPCR 






LV dimensions and systolic function were measured using two-dimensional and 
M-mode echocardiography with a VisualSonics Vevo 2100 high-resolution imaging 
system (Toronto, Canada) equipped with a 22-55-MHz MS550D transducer, as we  have 
previously described 109. Mice were anaesthetized with isoflurane by facemask at a 
concentration of 2.5% for induction and then 1.5% for maintenance. LV anterior wall 
thickness (AWT), posterior wall thickness (PWT), end-diastolic (EDD) and end-systolic 
(ESD) dimensions were measured from the M-mode image. LV fractional shortening (FS) 
was calculated as (EDD–ESD)/EDD × 100. LV diastolic function was assessed by trans-
mitral and tissue Doppler echocardiography. Pulsed-wave Doppler images were collected 
in the apical four-chamber view to record the mitral Doppler flow spectra. Peak early (E) 
and late (A) mitral inflow velocities and E/A ratio were measured. Tissue Doppler images 
were collected in the apical four-chamber view to record myocardial tissue movement at 
the mitral annulus. Myocardial peak early diastolic velocity (Em) was measured. Data 
analysis was performed offline using a customized version of Vevo 2100 Analytic 
software. 
Histology 
Left ventricle (LV) samples were fixed in 10% buffered formalin, embedded with 
paraffin, and sectioned. Myocyte cross-sectional area was measured as we previously 
described 109. In brief, sections stained with hematoxylin and eosin were examined under 




from each mouse were measured. Only round myocytes with central nuclei were included. 
Cross-sectional area of the myocyte was measured using NIH ImageJ software.  
Immunohistochemistry for 4-hydroxy-2-nonenal 
Immunohistochemistry for 4-hydroxy-2-nonenal (HNE) was performed as we 
previously described 35. In brief, LV tissue sections were blocked with 10% goat serum in 
PBS, then incubated with mouse anti-HNE monoclonal antibody (OXIS International). 
Sections were then incubated with goat biotin-conjugated anti-mouse IgG (Vector 
Laboratory) and then incubated with avidin and biotinylated horseradish peroxidase 
macromolecular complex (Vector Laboratory). Sections were then stained with 3-amino-
9-ethylcarbazole (Vector Laboratory) and hematoxylin (Vector Laboratory). The samples 
were then examined under a light microscope (BX 40, Olympus). 20-50 random fields from 
3 sections from each mouse were then scored by a blinded reviewer.  
Mitochondrial Isolation 
Cardiac mitochondria were isolated as we previously described 76,110. In brief, 
hearts  were washed and minced in ice-cold relaxation buffer (100 mM KCl, 5 mM EGTA, 
and 5 mM HEPES buffer at pH 7.0), then homogenized in 2 mL of HES buffer (HEPES 5 
mM, EDTA 1 mM, and sucrose 0.25 M at pH 7.4) using a Teflon-on-glass homogenizer, 
and centrifuged for 10 min at 500 g at 4° C. The supernatant was then centrifuged at 9000 
g for 15 minutes at 4° C and the pellet was resuspended in 100 µl HES buffer. Protein was 




Mitochondrial Oxygen Consumption Rate 
Mitochondrial oxygen consumption rates were measured using a Seahorse XF24 
oxygen flux analyzer, as we previously described 24. Isolated mitochondria were loaded 
onto a 24-well Seahorse plate on ice (5-12.5 ug/well) and 440 µl of ice-cold mitochondrial 
assay solution (MAS: 70 mM sucrose, 220 mM mannitol, 5 mM KH2PO4, 5 mM MgCl2, 
2 mM HEPES, 1 mM EGTA, 0.3% BSA fatty acid free at pH 7.4) and 10x substrates 
(complex I: 50 mM pyruvate and 50 mM malate; complex II: 50 mM succinate and 20 µM 
rotenone in MAS) were added. The 4 sequential injection ports of the Seahorse cartridge 
contained the following: port A- 50 μL of 10× substrate and 2.5 mM ADP; port B-55 μL 
of 20 μM oligomycin; port C- 60 μL of 40 μM FCCP and port D- 65 μL of 40 μM 
antimycin A. State III was determined after port A injection. State IV was determined after 
port B injection. Antimycin A was used as a control to block the electron transport chain 
to minimize oxygen consumption. The results are reported as pmol oxygen/min/µg protein.  
Mitochondrial Hydrogen Peroxide Production 
Mitochondrial hydrogen peroxide production was measured using the Amplex 
Ultra Red horseradish peroxidase method (Invitrogen), as we previously reported 111. In 
brief, 10 µg of isolated mitochondria were diluted in 40 µl of reaction buffer (125 mM KCl, 
10 mM HEPES, 5 mM MgCl2, 2 mM K2HPO4 at pH 7.44). Mitochondria were mixed with 
complex I substrates (5 mM pyruvate, 5 mM malate) or complex II substrates (5 mM 
succinate, 2 µM rotenone). H2O2 production was measured after the addition of 50 µl 
reaction buffer, containing horseradish peroxidase and Amplex Ultra Red, by measuring 




nm for 20 minutes. Wells containing catalase were used as background controls. The slope 
of the increase in fluorescence was converted to the rate of H2O2 production with a standard 
curve. All steps of the assay were performed at 25° C. Results are reported as percent 
control, compared to wild type samples. 
Microarray Analysis 
The microarray analysis was conducted by the BU Microarray and Sequencing 
Resource Core Facility. Methods for the microarray analysis were provided by the BU 
Microarray and Sequencing Resource Core Facility. Clariom S Mouse CEL files were 
normalized to produce gene-level expression values with the  Robust Multiarray Average 
(RMA) 112 using the affy R package (version 1.58.0) and Entrez Gene-specific R packages 
(version 23.0.0) from the Molecular and Behavioral Neuroscience Institute (Brainarray) at 
the University of Michigan 113. Gene biotypes were obtained using the biomaRt R package 
(version 2.38.0). Gene Ontology (GO) terms and Kyoto Encylopedia of Genes and 
Genomes (KEGG) pathways were obtained using the GO.db and KEGG.db packages 
(versions 3.7.0 and 3.2.3, respectively). Array quality was assessed by computing Relative 
Log Expression (RLE) and Normalized Unscaled Standard Error (NUSE) using the 
affyPLM R package (version 1.58.0). Principal Component Analysis (PCA) was performed 
using the prcomp R function with expression values that had been normalized across all 
samples to a mean of zero and a standard deviation of one. Differential expression was 
assessed using the moderated (empirical Bayesian) t test implemented in the limma R 
package (version 3.38.3). Correction for multiple hypothesis testing was accomplished 




genes were identified using HomoloGene (version 68). All microarray analyses were 
performed using the R environment for statistical computing (version 3.5.1). 
Gene Set Enrichment Analysis 
The gene set enrichment analysis (GSEA) was conducted by the BU Microarray 
and Sequencing Resource Core Facility. Methods for the GSEA were provided by the BU 
Microarray and Sequencing Resource Core Facility. GSEA (version 2.2.1) 115  was used to 
identify biological terms, pathways and processes that are coordinately up- or down-
regulated within each pairwise comparison. The Entrez Gene identifiers of the human 
homologs of the genes interrogated by the array were ranked according to the moderated t 
statistic. Any mouse genes with multiple human homologs (or vice versa) were removed 
prior to ranking, so that the ranked list represents only those human genes that match 
exactly one mouse gene. This ranked list was then used to perform pre-ranked GSEA 
analyses (default parameters with random seed 1234) using the Entrez Gene versions of 
the Hallmark, Biocarta, KEGG, Reactome, Gene Ontology (GO), and transcription factor 
and microRNA motif gene sets obtained from the Molecular Signatures Database 
(MSigDB), version 6.0 116. 
Statistical Analysis 
Results are presented as mean ± SEM. For experiments with two conditions, the 
statistical significance of comparisons between groups was determined using unpaired two 
tailed t tests. For experiments with more than two conditions, the statistical significance of 




correction.  For the survival study, statistical significance was determined using the 
Mantel-Cox test. A P value < 0.05 was considered significant.  
 
 











ATP-Binding Cassette Protein 10 (ABCB10) exports an unknown substrate from 
the mitochondrial inner matrix. We have previously identified ABCB10 as a possible 
cardioprotective antioxidant 76. Our previous study found that hearts from mice with 
heterozygous global ABCB10 knockdown had impaired cardiac recovery and increased 
oxidative stress after ischemia/reperfusion 76. Administration of an antioxidant rescued the 
hearts from ABCB10 +/- mice, indicating that ABCB10 may function as an antioxidant in 
the heart. However, the mechanism of this antioxidant effect remains to be determined.  
ABCB10 has been linked to regulation of heme content, oxidative stress, and 
proteostasis; however, its exact function is still unknown. Previous studies show that 
ABCB10 regulates heme synthesis 46,47,53,54. Whole body ABCB10 knockout mice are 
neonatal lethal, due to impaired erythrogenesis 46,47. Deletion of ABCB10 from 
hematopoietic cells caused reticulocytes to accumulate protoporphyrin IX, reducing heme 
levels 47. Decreasing ABCB10 levels decreased heme content in variety of model systems 
including zebrafish 51, cardiac myoblasts 49, and mouse erythroleukemia cells 51.  
Heme is a necessary cofactor for many antioxidant enzymes, including catalase, 
and components of the electron transport chain 116. Additionally, free heme is a potent 
oxidant and a known inducer of Nrf2 68,70,117. Heme degradation via HO-1 generates the 
antioxidant bilirubin and the antiapoptotic molecule carbon monoxide (CO) 68,117. 
Therefore, by regulating heme synthesis, ABCB10 could possibly regulate the antioxidant 




I overexpressed ABCB10 in ARVMs and exposed them to an oxidant challenge. These 
studies can elucidate the role of ABCB10 in cardiac myocytes and provide insights into 
ABCB10’s therapeutic potential. 
Experiments 
Overexpression of ABCB10 in adult cardiac myocytes 
Adult rat ventricular cardiac myocytes (ARVMs) were transfected with 
adenoviruses to induce overexpression of either LacZ or ABCB10. Overexpression of 
ABCB10 was confirmed by protein level from ARVMs transfected for 48 hours (figure 
2.1). ABCB10 overexpression did not causes changes in cytosolic reactive oxygen species 
levels, ATP:ADP ratio, or cell survival basally. ABCB10 overexpression did lead to 
upregulation of components of complex II and complex V basally, although the impact of 
this upregulation remains to be determined (figure 3.1).  ABCB10 did not affect the levels 
of any other components of the electron transport chain.  
Figure 3.1. ABCB10 overexpression increased levels of components of CII and CV. 
Western blot analysis using the Total Oxphos Rodent Antibody Cocktail (Abcam) (n=4,  * 




ABCB10 overexpression attenuates ROS-induced cell death in ARVMs 
After 72 hours in culture, LacZ and ABCB10 ARVMs were treated with 500 µM 
H2O2 for 10 minutes. H2O2 exposure caused 34±6% (S.E) cell death in LacZ-expressing 
ARVMs (figure 3.2). ABCB10 overexpression decreased H2O2-induced cell death by 45% 
(figure 3.2), suggesting that ABCB10 can partially protect against oxidative stress-induced 
cell death in cardiac myocytes. 
 
Figure 3.2. Overexpression of ABCB10 in adult cardiac myocytes attenuates ROS-
induced cell death. Adult rat ventricular myocytes were treated with 500 uM H2O2 for 10 
minutes. Cell viability was measured using trypan blue. *, p<0.05, LacZ vs LacZ + H2O2; 
#, p<0.05 LacZ H2O2  vs ABCB10 H2O2 (300 cells counted for each plate, n=6).   
ABCB10 overexpression increases the cardiac myocyte’s ability to scavenge ROS 
I next investigated how ABCB10 exerts its cardioprotective effect. Using the 
fluorescent H2O2 sensor, HyPer, we measured cytosolic and mitochondrial H2O2 levels 
after H2O2 treatment (500 µM, 10 minutes). There was no baseline difference in either 




expressing ARVMs, cytosolic H2O2 levels increased rapidly and plateaued at a 3-fold 
increase 2 minutes post- H2O2 exposure (figure 3.3). ABCB10 overexpression reduced the 
peak cytosolic H2O2 levels by 37±7% (S.E) (figure 3.4). In addition, cytosolic H2O2 levels 
recovered faster in ABCB10 ARVMs than in LacZ ARVMs (figure 3.3), demonstrating 
that ABCB10 overexpression improves the cardiac myocyte’s ability to scavenge H2O2.  
 
Figure 3.3. ABCB10 overexpression increases the cardiac myocyte’s ability to 
scavenge ROS. Cytoplasmic H2O2 levels were measured using the HyPer probe. ARVMs 
were treated with 500 uM H2O2 at time zero and imaged over a 10 minute period. A) 
Representative trace of H2O2 levels in ARVMs expressing Hyper and either LacZ or 
ABCB10 during 10 minutes of 500 uM H2O2 treatment (average of 5 cells). B) Quantitation 
of the fold change in cytoplasmic H2O2 levels at 0 minutes, 5 minutes and 10 minutes. *, 
p<0.05, LacZ vs ABCB10 at that time point (n=4).  












































Figure 3.4. ABCB10 decreases mitochondrial H2O2 after oxidative challenge. 
Mitochondrial H2O2 levels were measured using the HyPer probe targeted to mitochondria. 
A) Representative trace of H2O2 levels in ARVMs expressing mitoHyper and either LacZ 
or ABCB10 during 10 minutes of 500 uM H2O2 treatment (average of 5 cells). B) 
Quantitation of the fold change in cytoplasmic H2O2 levels at 0, minutes, 5 minutes and 10 
minutes. (n=4).  
 
Mitochondrial H2O2 levels showed similar trends to the cytosolic. In LacZ 
overexpressing ARVMs, mitochondrial H2O2 began to rise approximately 3 minutes after 
H2O2 exposure and plateaued at a 3-fold increase 7 minutes post-H2O2 exposure (figure 
3.4). Mitochondrial H2O2 levels in ABCB10 ARVMs began to rise 1-minute post-H2O2 
exposure and plateaued at a 2-fold increase 4 minutes post-H2O2 exposure. ABCB10 
overexpression caused a 17±0.05% decrease in peak mitochondrial H2O2 levels compared 









































to LacZ ARVMs (figure 3.4). Additionally, mitochondrial H2O2 levels recovered faster in 
ABCB10 ARVMs than LacZ ARVMs. Mitochondrial H2O2 levels only declined 
1.45±0.09% from peak levels in LacZ ARVMs, compared to the 15±6% decline observed 
in ABCB10 ARVMs. Taken together, these data demonstrate that ABCB10 increases the 
cardiac myocytes capacity to scavenge ROS, both in the cytoplasm and in the 
mitochondria.  
ABCB10 increases the cell’s antioxidant capacity by upregulating HO-1 
To determine how ABCB10 increases the cell’s antioxidant capacity, I screened the 
transcript levels of various antioxidant enzymes in LacZ and ABCB10 overexpressing 
ARVMs. RNA was isolated from LacZ and ABCB10 ARVMs after 72 hours in culture. 
mRNA levels of eight antioxidant proteins (Sirt1, Nrf2, catalase, Sod1, Sod2, biliverdin 
reductase, Hif1α & HO-1) were measured by qRT-PCR. ABCB10 overexpression caused 
a 3.5±0.76 fold increase in HO-1 mRNA, but ABCB10 overexpression did not induce 
upregulation of any other antioxidant enzyme measured, including Nrf2 and its 
downstream target genes catalase, Sod1, or Sod2 (figure 3.5). ABCB10 ARVMs had a 
45±15% increase in HO-1 protein level after 72 hours in culture (figure 3.6), confirming 
the upregulation of HO-1.  
To determine if this upregulation of HO-1 is responsible for ABCB10’s protective 
effect against H2O2-induced cell death, I inhibited HO-1 with ZnPPIX (10 µM overnight) 
in both LacZ and ABCB10 ARVMs and measured cell survival after H2O2 exposure. 




in ABCB10 ARVMs (figure 3.7). These findings indicate that HO-1 mediates ABCB10’s 
protective phenotype, but more n is necessary to confirm this hypothesis.  
 
Figure 3.5. ABCB10 selectively upregulates HO-1 mRNA. RNA was isolated from LacZ 
and ABCB10 ARVMs after 72 hours in culture. mRNA levels were measured using qRT-
PCR. ABCB10 overexpression caused a 3.5±0.76 fold increase in HO-1 mRNA and did 
not significantly alter the mRNA levels of Nrf or any of its downstream targets, including 
catalase, Sod1, and Sod2. **, p<0.01, LacZ vs ABCB10, n=3-5 
 
Figure 3.6. ABCB10 upregulates HO-1. Protein was isolated from LacZ and ABCB10 
ARVMs 72 hours after addition of the adenoviral vector. Western blot of heme oxygenase 




Figure 3.7. HO-1 inhibition may prevent ABCB10 from protecting against H2O2-
induced cell death. ARVMs expressing LacZ or ABCB10 were treated with 10 µM 
ZnPPIX or DMF overnight. ARVMs were then exposed to H2O2 for 10 minutes. Cell 
survival was measured with trypan blue. Cell survival was normalized to that day’s 
LacZ+H2O2 viability. ZnPPIX reduced cell survival after H2O2 exposure in ABCB10 
ARVMs. Red lines connect measurements done on the same day.  
An initial increase in heme leads to HO-1 upregulation in ABCB10 ARVMs 
Since heme is a known inducer of HO-1, we measured heme content early after 
ABCB10 overexpression, prior to the induction of HO-1 118. 40 hours after the addition of 
the adenoviral vector, ABCB10 overexpression increased heme content by 27±7% (figure 
3.8). This early increase in heme likely leads to the induction of HO-1 at 72 hours. ABCB10 
OE ARVMs do not maintain elevated heme levels. By 72 hours, ABCB10 overexpression 
caused a 22±5% decrease in heme content (figure 3.8), possibly due to increased heme 





Figure 3.8. ABCB10 regulates heme in a biphasic manner. Heme content was measured 
in extracts from LacZ and ABCB10 OE ARVMs via oxalic acid extraction. A) Heme 
content was measured 40 hours after addition of the adenoviral vector. ABCB10 
overexpression caused a 27±7% increase in heme content (*, p<0.05, LacZ vs ABCB10, 
n=4). B) Heme content was measured 72 hours after additional of the adenoviral vector. 
ABCB10 overexpression caused a 22±5% decrease in heme (*, p<0.05, LacZ vs ABCB10, 
n=3) 
ABCB10 overexpression increases AMPK activation after H2O2 exposure 
AMPK is a known cardioprotective enzyme and a master regulator of energy 
balance in the cell 119. Low ATP and high ADP conditions activate AMPK, which then 
inhibits energy consuming processes and activates energy producing processes 119,120. 
Activated AMPK is phosphorylated at Thr172 120. Since H2O2 is a known activator of 
AMPK 121–124, I measured phosphorylated AMPK in LacZ and ABCB10 ARVMs basally 
and after 10 minutes of 500 µM H2O2. ABCB10 ARVMs had a modest increase in AMPK 
phosphorylation basally compared to LacZ ARVMs (figure 3.9). H2O2 caused a 2-fold 
increase in pAMPK in LacZ ARVMs, while H2O2 caused a 6-fold increase in pAMPK in 




To determine how ABCB10 ARVMs activated AMPK, I measured ATP:ADP ratio 
in real time in LacZ and ABCB10 ARVMs exposed to H2O2 using Perceval-HR, a 
fluorescent ratiometric ATP:ADP probe. A low ATP:ADP ratio should activate AMPK. A 
baseline image was taken at time 0 and then a bolus of 500 µM H2O2 was added and the 
cells were imaged every 30 seconds over the next five minutes. There was no significant 
difference in ATP:ADP ratio at baseline between LacZ and ABCB10 cells (figure 3.10). 
ATP:ADP ratio did not significantly change in LacZ cells after H2O2 challenge, decreasing 
only 5% after 5 minutes. However, over the five-minute period the ATP:ADP ratio in 
ABCB10 ARVMs declined by 36%. By five minutes, ABCB10 ARVMs had a significant 
decrease in ATP:ADP ratio (p<0.01, n=4). This severe drop in ATP:ADP ratio likely led 





Figure 3.9. ABCB10 increases AMPK phosphorylation after H2O2 administration. 
Phosphorylation of Thr172 in AMPK was measured by Western Blot in LacZ and ABCB10 
ARVMs either basally or after 10 minutes of H2O2. ABCB10 induced a 6-fold increase in 
pAMPK after H2O2, compared to the 2-fold increase seen in LacZ ARVMs. (**, p<0.01, 







Figure 3.10. ATP:ADP ratio decreases in ABCB10 ARVMs after H2O2 exposure. 
Cytosolic ATP:ADP ratio was measured using the fluorescent probe, Perceval. 500 µM 
H2O2 was added at time zero and then images were taken every 30 seconds for the next 5 
minutes. ABCB10 caused a ~35% decrease in ATP:ADP ratio after 5 minutes of H2O2, 
while LacZ expression did not affect ATP:ADP ratio. (*, p<0.05 LacZ vs ABCB10; **, 
p<0.01, LacZ vs ABCB10, n=5). 
Activation of AMPK is necessary for ABCB10 to protect against ROS-induced cell death 
The previous data showed that ABCB10 can activate AMPK in response to an 
oxidative challenge. To test if this activation of AMPK is responsible for ABCB10’s 
protection against ROS-induced cell death, I treated LacZ and ABCB10 ARVMs overnight 
with Compound C (10 µM), a potent inhibitor of AMPK, and measured cell viability after 
H2O2 exposure. Compound C treatment did not affect basal cell viability in either LacZ or 
ABCB10 ARVMs (figure 3.11). Additionally, Compound C did not affect LacZ cell 
viability after H2O2 exposure. However, Compound C treatment reduced cell viability by 
43% in ABCB10 ARVMs exposed to H2O2. These findings demonstrate that AMPK 





Figure 3.11. AMPK is necessary for ABCB10 to protect against H2O2-induced cell 
death. ARVMs treated with 10 µM Compound C overnight and then exposed to 500 uM 
H2O2 for 10 minutes. Cell viability was measured using trypan blue. **, p<0.01, ABCB10 
+ H2O2 vs ABCB10 + H2O2 + Compound C (300 cells counted for each plate, n=4). 
Discussion 
In this chapter, we provide several new insights regarding the role of ABCB10 in 
the cardiac myocyte. First, we show that ABCB10 overexpression protects cardiac 
myocytes against H2O2-induced cell death. Second, ABCB10 overexpression increases the 
antioxidant capacity of the cardiac myocyte, as evidenced by attenuating the peak in ROS 
post-H2O2. Third, ABCB10 can induce upregulation of the cardioprotective enzyme HO-
1, most likely by increasing heme levels early. Finally, ABCB10 can increase ROS-induced 




to the antioxidant system in the cardiac myocyte by regulating heme levels and HO-1 and 
that ABCB10 plays a cardioprotective in response to an oxidative challenge. 
ABCB10 exerts an antioxidant effect 
Overexpression of ABCB10 in cardiac myocytes improved cell survival in response 
to an oxidative insult. This cardioprotective effect was associated with an increase in the 
antioxidant capacity of the myocyte, as reflected by decreased cytosolic H2O2 levels 
measured by HyPer and increased HO-1 levels. The finding that ABCB10 can increase the 
antioxidant capacity of the cardiac myocyte is consistent with our previous study in mice 
with a global heterozygous knock-down of ABCB10 76. In these mice ischemia/reperfusion 
caused more severe myocardial dysfunction, which was rescued by an antioxidant, thus 
suggesting that ABCB10 played a role in the antioxidant defense of the heart. Our current 
study demonstrates that ABCB10 exerts an antioxidant effect in the cardiac myocyte. 
Consistent with our conclusion, it was shown that in cardiac myoblasts hypoxia caused 
upregulation of ABCB10, inhibition of which led to increased ROS levels and cell death 
49. Likewise, in a striatal cell model of Huntingtin’s disease overexpression of ABCB10 
reduced mitochondrial ROS production 85.  
While prior studies have suggested an antioxidant effect of ABCB10, the 
mechanism has not been elucidated. While overexpression  of ABCB10 did not upregulate 
catalase, superoxide dismutase-1 or -2, or Nrf2, it caused a marked upregulation of HO-1. 
HO-1 acts on heme to generate the antioxidant bilirubin and carbon monoxide (CO) 72,125–
127. Bilirubin is a potent antioxidant that can freely cross membranes 72,128–131. Modest 




serum protein oxidation in humans 132,133. Furthermore, serum total bilirubin levels are 
negatively correlated with left ventricle diastolic dysfunction in patient with heart failure 
with preserved ejection fraction 134. CO has both anti-inflammatory and anti-apoptotic 
actions 135,136. It can activate various hemoproteins, including guanylate cyclase leading to 
increased cGMP levels, and can also regulate MAPK activities 70. CO can also reduce 
inflammation by activating Hif-1α 137.  Based on the protective effects of both bilirubin and 
carbon monoxide, HO-1 has long been investigated as a potential therapeutic target for 
cardiovascular disease.  
Extensive studies over the last twenty years have shown that HO-1 is protective 
against both hypoxia and ischemia/reperfusion 138–143. Increasing HO-1 levels or enzymatic 
activity prior to ischemia attenuated cardiac dysfunction in isolated rat hearts and in vivo 
in mice and rats 144–147. Treatment with exogenous bilirubin or exogenous carbon monoxide 
mimicked the protective phenotype of HO-1 induction 144,145. Overexpression of HO-1 
specifically in the heart reduced infarct size and decreased oxidative damage in both rat 
and mouse models of myocardial infarction 148,149, and protected against myocardial 
ischemic injury in diabetic mice, reducing infarct size 94. HO-1 induction in the myocyte 
protected against coronary ligation-induced heart failure in mice, improving survival and 
cardiac function, while decreasing cardiac hypertrophy and oxidative stress 150. HO-1 also 
protects against pressure overload, improving cardiac hypertrophy, contractile function, 
and reducing fibrosis 151. HO-1 does not just provide acute protection against myocardial 
injury. HO-1 gene therapy improved cardiac function and reduced cardiac scarring one 




small animal models. HO-1 overexpression reduced infarct size, inflammation, and 
improved systolic function in porcine ischemia/reperfusion studies 153,154. These extensive 
studies demonstrate that HO-1 can protect the heart against both acute and chronic injury, 
particularly by modulating inflammation, apoptosis, fibrosis, and oxidative stress 70. 
ABCB10’s upregulation of HO-1 could explain our previous finding that hearts from 
global heterozygous ABCB10 knockout mice were more susceptible to 
ischemia/reperfusion. ABCB10 knockdown could possibly inhibit induction of HO-1 
during ischemia/reperfusion, which would increase oxidative stress, apoptosis, and 
decrease cardiac recovery.  
While there is a large body of evidence supporting the cardioprotective role of HO-
1, the relationship between HO-1 and mitochondrial function is more complicated. HO-1 
overexpression improves mitochondrial membrane potential and decreases mitochondrial 
ROS production in hypoxic cardiac myoblasts 143. Both HO-1 induction and bilirubin 
treatment reduced mitochondrial swelling after ischemia/reperfusion in isolated rat hearts 
144. Overexpression of HO-1, as well as carbon monoxide treatment protected against 
doxorubicin-induced cardiomyopathy, increasing mitochondrial biogenesis, reducing 
mitochondrial fragmentation, and reducing mitochondrial oxidative damage 155,156. Mice 
lacking HO-1 are more susceptible to oxidative stress and have impaired mitochondrial 
quality control 157. Treatment with a CO-releasing molecule, CORM-3, restored 
mitochondrial membrane potential, improved mitochondrial energetics, and increased 
mitochondrial biogenesis after sepsis, although it did induce modest mitochondrial 




function in a mouse model of metabolic heart disease, improving mitochondrial membrane 
potential and modulating mitochondrial biogenesis 159. Myocyte-specific overexpression of 
HO-1 attenuated coronary ligation-induced heart failure, fibrosis, oxidative stress, and 
apoptosis; however, HO-1 overexpression also reduced mitochondrial respiration in a CO-
dependent manner 155. CO  can bind to and inhibit cytochrome c oxidase, a key component 
of the electron transport chain 161,162. Therefore, by increasing CO levels HO-1 could 
possibly reduce mitochondrial respiration. Mitochondria isolated from rats with increased 
HO-1 expression had reduced oxygen uptake 150. CORM-3 administration uncoupled 
mitochondrial respiration in a CO-dependent manner and increased mitochondrial ROS 
production 161,163. It appears that HO-1 has conflicting roles in regulating mitochondrial 
function. HO-1 can increase mitochondrial quality control and protect mitochondria from 
various stressors; however, HO-1 produces CO, which can reduce mitochondrial function 
by binding to cytochrome c oxidase. It is possible that ABCB10’s upregulation of HO-1 
has altered mitochondrial respiration or quality control in cardiac myocytes.  
ABCB10’s upregulation of HO-1 is likely cardioprotective. HO-1 increases the 
cardiac myocyte’s capacity to scavenge ROS, due to increased levels of bilirubin. HO-1 
also inhibits apoptosis, by increasing CO levels. It is possible that this upregulation of HO-
1 has altered mitochondrial function. ATP:ADP ratio does decline more in ABCB10 
overexpressing ARVMs than in LacZ ARVMs. However, it is also possible that HO-1 
protects mitochondria from oxidative damage. Mitochondrial respiration studies are 




ABCB10’s regulation of HO-1 supports our previous finding that ABCB10 +/- hearts are 
more susceptible to ischemic injury.  
ABCB10 overexpression causes an early increase in heme 
ABCB10 overexpression caused an early increase in myocyte heme measured 40 
hours after addition of the adenoviral vector. Heme is a well-known inducer of HO-1 
68,70,117 which acts by interacting with Bach1 and Nrf2 116. Bach1 binds to the enhancer 
regions of HO-1’s promotor, preventing Nrf2 from binding to and upregulating HO-1. 
When heme binds to Bach1, it displaces Bach1 from HO-1’s promoter, enabling Nrf2 to 
bind to the enhancer regions and induce expression of HO-1 116. At 72 hours after 
transfection with the ABCB10 vector, heme levels fell, likely reflecting oxidation by the 
induced HO-1 and leading to the generation of bilirubin and CO (figure 3.11). Our finding 
of increased heme is consistent with the observation that in mouse erythroleukemia cells 
ABCB10 overexpression increased hemoglobin synthesis during DMSO-induced 
differentiation 43. The mechanism by which ABCB10 increases heme levels and 





Figure 3.11. Proposed Mechanism for how ABCB10 protects against oxidative 
challenge in cardiac myocytes. 1. ABCB10 is overexpressed in ARVMs. 2. After 40 hours 
in culture, ABCB10 overexpression increases heme content. 3. Increased heme content 
increases HO-1 levels, possibly by inhibiting Bach1. 4. HO-1 generates the antioxidant 
bilirubin (BR), increasing the cells antioxidant capacity. 5. Bilirubin and carbon monoxide 
(CO) both inhibit cell death, by reducing ROS levels and inhibiting apoptosis signaling. 
 
 Our findings differ from a prior study in which overexpression of ABCB10 in 
cardiac myoblasts had no effect on heme content 49. Given our finding that the effect of 
ABCB10 on heme levels is biphasic, it is possible that these differences reflect differing 
lengths of ABCB10 overexpression. It is also possible that the effect of ABCB10 
overexpression may be less in immature versus mature cardiac myocyte, which have a 
greater density of mitochondria. The mechanism by which ABCB10 regulates heme 
synthesis is not clear. It was suggested that ABCB10 regulates heme synthesis by exporting 




export ALA, a more recent study suggested that ABCB10 exports a molecule that can 
regulate nuclear transcription of heme synthesis enzymes 51.  
Activation of AMPK mediates ABCB10’s cardioprotective effect 
We showed for the first time that ABCB10 can increase AMPK activation after 
oxidative challenge. ABCB10 ARVMs had a modest, but not significant, increase in 
phosphorylated AMPK basally. In LacZ ARVMs, H2O2 exposure increased 
phosphorylation of AMPK 2-fold; however, in ABCB10 ARVMs phosphorylated AMPK 
increased 6-fold after H2O2. Treatment with the AMPK inhibitor compound C blunts 
ABCB10’s protective effect against ROS-induced cell death, indicating that this activation 
of AMPK is necessary for ABCB10 to protect against H2O2-induced cell death. 
Interestingly, AMPK activation can increase the Nrf2 HO-1 signaling axis 165.  
 Exactly how ABCB10 activates AMPK is still unclear. ABCB10 ARVMs had a 
significant decrease in ATP:ADP ratio after H2O2 exposure. This change in the ATP:ADP 
ratio could activate AMPK, which is known to be regulated by decreasing ATP levels or 
increasing AMP levels 120,164. There are few possible explanations for why ATP:ADP 
declines so sharply in ABCB10 ARVMs. ABCB10 is an ATPase and increased ABCB10 
activity would consume ATP, generating ADP. If ABCB10 is activated by H2O2 exposure, 
it is possible that ATP:ADP ratio would decrease, as ABCB10 consumes ATP to fuel its 
export function, generating ADP. ABCB10 can be glutathionylated, an oxidative 
modification that often affects the activity of enzymes 50. Furthermore, it has been shown 
that oxidized glutathione stimulates ABCB10’s ATPase activity 50. Therefore, it is quite 




It is also possible that the change in the ATP:ADP ratio is fueled by secondary 
effects from ABCB10 overexpression. ABCB10 overexpression did increase levels of 
some components of the electron transport chain. If ABCB10 exports a substrate capable 
of nuclear signaling, then a multitude of genes could be changed by ABCB10 
overexpression. This shift in the cellular milieu could affect the energy response to an 
oxidative challenge. Finally, it has been shown that increased heme levels can lead to 
AMPK activation 166. We found that ABCB10 increased heme levels early. Potentially, this 
initial increase in heme led to a modest activation of AMPK, priming the cell for future 
stress. However, phosphorylation is not a permanent modification and heme levels   decline 
72 hours after the addition of the ABCB10 vector. Therefore, it is unlikely that heme is 
responsible for the large activation of AMPK post-H2O2 in ABCB10 ARVMs.  
Conclusions 
In conclusion, this study demonstrates that ABCB10 is part of the antioxidant 
defense system of the cardiac myocyte. In this chapter we showed that ABCB10 can protect 
cardiac myocytes against oxidative challenge by increasing the cells antioxidant capacity. 
We also demonstrated that ABCB10 can upregulate the HO-1 antioxidant system and 
activate AMPK. Finally, we showed that ABCB10 regulates heme content in a biphasic 
manner, increasing heme levels initially followed by a later decrease in heme levels. These 
findings, along with our prior study in mice with heterozygous global knockout of 
ABCB10, demonstrate that ABCB10 can protect the cardiac myocyte from pathological 




 Targeting antioxidants to the mitochondria through pharmacological interventions 
or transgenic approaches can protect against myocardial dysfunction and failure in a variety 
of pathological conditions 35,36,167. Identification of the antioxidant role of ABCB10 in the 
cardiac myocyte provides a new potential therapeutic target for the therapy of conditions 










In Chapter 3, we showed that ABCB10 can protect against oxidative challenge in 
adult rat ventricular myocytes. ABCB10 overexpression decreased cytosolic ROS levels, 
and improved cell survival after H2O2 administration. Furthermore, ABCB10 increased 
levels of HO-1, likely due to an initial increase in heme content. While these studies 
demonstrate that ABCB10 can increase the antioxidant capacity of the cardiac myocyte, 
they do not establish the role of ABCB10 in normal expression levels.   
We showed previously that whole body heterozygous ABCB10 knockout mice had 
increased oxidative stress, decreased ATP content, and impaired cardiac recovery after 
ischemia/reperfusion 76. Administration of an antioxidant rescued the negative effects of 
ABCB10 depletion, supporting the hypothesis that ABCB10 has an antioxidant function in 
the heart 76. These findings demonstrate that ABCB10 is required for the heart to normally 
recover from ischemia/reperfusion. However, the heart contains numerous cell types and 
since this study was conducted in a whole body heterozygous ABCB10 knockout mouse, 
it is impossible to determine the role of ABCB10 in specific cell types.  
Therefore, for my studies, we generated a cardiomyocyte-specific ABCB10 
knockout mouse (CM-ABCB10 -/-). We hypothesized that ABCB10 regulates 
mitochondrial function and ROS production in the cardiac myocyte and that cardiac 
myocyte ABCB10 is necessary to maintain mitochondrial and cardiac function. 
Determining the role of ABCB10 in the cardiac myocyte could provide an explanation for 






Cardiac myocyte specific ABCB10 knockout mice die significantly earlier than wild type 
cre+ controls, but do not have increased cardiac dysfunction  
Whole body heterozygous ABCB10 knockout mice are more susceptible to 
ischemia/reperfusion, with decreased cardiac recovery, increased oxidative stress, and 
decreased ATP production 76. However, whole body heterozygous ABCB10 knockout 
mice had no overt basal cardiac phenotype, with normal cardiac mitochondrial function 76. 
Since this study was conducted in mice lacking ABCB10 throughout the body, we cannot 
determine the role or significance of cardiac-myocyte ABCB10.  
Therefore, to answer this question, we generated a cardiac myocyte-specific 
ABCB10 knockout mouse (CM-ABCB10 -/-) by crossing ABCB10 floxed/floxed mice 
with mice hemizygous for myosin heavy chain 6 cre recombinase (MHC-Cre) (see Chapter 
2 for more details). At four months of age, CM-ABCB10 -/- mice did not have altered 
cardiac structure (figure 4.1) or function (figure 4.2), as measured by echocardiography. 
As both CM-ABCB10 -/- and wild type Cre + (WT Cre+) mice aged, their cardiac function 
declined. By 8 months of age, Cre + mice (both wild type and CM-ABCB10 -/-) had 
increased cardiac hypertrophy (figure 4.3), decreased fractional shortening (figure 4.4), and 
diastolic dysfunction (figure 4.4). Total wall thickness decreased in WT Cre+ mice but did 
not change in CM-ABCB10 -/- mice.  At 8 months of age, CM-ABCB10 -/- mice did not 
have significantly altered myocyte size (figure 4.5) or 4-HNE levels, a marker of oxidative 




Cre + and is likely caused by constitutively active Cre recombinase targeting nonspecific 
sites, leading to DNA damage 168. Since cardiac myocytes have very little cell turnover, 
they are particularly susceptible Cre toxicity and DNA damage.  
 
Figure 4.1. ABCB10 deletion in young mice does not alter cardiac structure. 
Echocardiography measurements taken from 4-month-old WT, CM-ABCB10 +/-, and 





Figure 4.2. ABCB10 deletion in young mice does not alter cardiac function. 
Echocardiography measurements taken from 4-month-old WT, CM-ABCB10 +/-, and 





Figure 4.3. Cre increases cardiac hypertrophy at 8 months of age. Echocardiography 
measurements taken from 8-month-old WT f/f, WT Cre+, and CM-ABCB10 -/- mice. A) 
End diastolic diameter significantly increased in both Cre+ genotypes. B) End systolic 
diameter significantly increased in both Cre+ genotypes. (C) Total wall thickness 
significantly decreased in WT Cre+, but not CM-ABCB10 -/-, mice. (**, p<0.01, compared 





Figure 4.4. Cre decreases cardiac function at 8 months of age. Echocardiography 
measurements taken from 8-month-old WT f/f, WT Cre+, and CM-ABCB10 -/- mice. A) 
Fractional shortening significantly decreased in both cre+ genotypes B) E/A Ratio trended 
to increase in Cre+ genotypes. (C) Em significantly decreased in both Cre+ genotypes. (*, 






Figure 4.5. Cre toxicity does not affect myocyte size. Myocyte cross sectional area was 
measured in sections from 8-month-old WT, WT cre+, and CM-ABCB10 -/- hearts stained 






Figure 4.6. CM-ABCB10 -/- hearts do not have increased HNE adducts at 8 months 
of age. Sections from 8-month-old WT, WT cre+, and CM-ABCB10 -/- hearts stained for 
HNE using immunohistochemistry A) Quantitation of myocyte cross-sectional area (n=2-
4) B) Representative images  
 
Interestingly, we observed that CM-ABCB10 -/- mice die significantly earlier than 
WT cre+ controls (figure 4.7). At 10 months of age, only 39% of CM-ABCB10 -/- mice 
were still living (n=9/23), while 81% of WT cre+ mice (n=9/11) were still living. This early 
death phenotype is particularly interesting, since at 8 months of age CM-ABCB10 -/- mice 





Figure 4.7. CM-ABCB10 -/- mice die significantly earlier than WT Cre+ controls. 
Kaplein-Meier survival curves for WT flox/flox (solid black), WT cre+ (orange), and 
ABCB10 F/F Cre+ (red). At 10 months of age, 39% of CM-ABCB10 -/- mice were still 
living (n=9/23), while 81% of WT cre+ mice were still living (n=9/11) (p=0.0103). 
 
To determine if cardiac function declines faster in CM-ABCB10 -/- mice, we 
measured cardiac function, via echocardiography, in WT cre+ and CM-ABCB10 -/- mice 
every two weeks from 5.5 months of age to 7 months of age. Cardiac hypertrophy (end 
systolic dimension and end diastolic dimension) increased at similar rates in both WT cre+ 
and CM-ABCB10 -/- mice (figure 4.8). Total wall thickness was maintained in both WT 
cre+ and WT floxed/floxed mice; however, at 6.5 months of age total wall thickness 
declined in two of the three CM-ABCB10 -/- mice (figure 4.8). Both mice were female, 
while all the WT cre+ were male, so this decline may be related to gender. There was no 
difference in fractional shortening decline between the two groups (figure 4.9). Peak early 
diastolic velocity (Em), a measure of left ventricle relaxation and diastolic function, 
decreased at similar rates between both groups (figure 4.9). E/A ratio, another measure of 




CM-ABCB10 -/- mice; however, at 6.5 months of age E/A ratio more than doubled in one 
of the female CM-ABCB10 -/- mice (figure 4.9). An E/A ratio greater than 2 is indicative 
of restrictive filling pattern, which is a marker of restrictive heart failure where the heart 
becomes rigid and can no longer stretch. Cardiac function does not appear to decline faster 
in CM-ABCB10 -/- mice than WT Cre+ mice; however, the phenotype of Cre toxicity is 
highly mosaic.  
 
Figure 4.8. WT Cre+ and CM-ABCB10 -/- mice develop cardiac hypertrophy at 
similar rates. Serial echocardiography measurements in WT, WT Cre+, and CM-ABCB10 
-/- mice from 5.5-7 months of age. Each line represents a mouse. A) End diastolic diameter 





Figure 4.9. WT Cre+ and CM-ABCB10 -/- mice have similar declines in cardiac 
function. Serial echocardiography measurements in WT, WT Cre+, and CM-ABCB10 -/- 
mice from 5.5-7 months of age. Each line represents a mouse. A) Fractional Shortening B) 
Peak early diastolic velocity (Em) C) E/A ratio 
 
Young CM-ABCB10 -/- mice have increased mitochondrial dysfunction 
To determine if lack of ABCB10 had any specific effect on cardiac mitochondria, 
we isolated mitochondria from 4-month-old WT flox/flox and CM-ABCB10 -/- hearts. 




production and a 14±8% increase in complex II driven ROS production (figure 4.10). CM-
ABCB10 -/- mitochondria also had 36±8% lower state III oxygen consumption and 
53±18% lower state IV oxygen consumption compared to wild type controls (figure 4.10). 
This mitochondrial dysfunction precedes any signs of Cre toxicity, indicating that 
mitochondrial dysfunction is one of the earliest phenotypes of ABCB10 deletion. It is 
possible that prolonged excess ROS production damaged proteins, lipid membranes, and 
DNA in the cardiac myocyte, exacerbating the DNA damage induced by Cre toxicity, and 
leading to the early death we observed in the CM-ABCB10 -/- mice. These data 
demonstrate that ABCB10 is necessary to maintain normal mitochondrial function in 
cardiac mitochondria and that lack of ABCB10 is sufficient to induce excess ROS 
production.  
 
Figure 4.10. ABCB10 deletion causes mitochondrial dysfunction. Mitochondria were 
isolated from 4-month-old WT and CM-ABCB10 -/- hearts. A) H2O2 production was 
measured using Amplex Ultra Red and driven by both complex I (pyruvate and malate) 
and complex II (succinate and rotenone) substrates. B) Oxygen consumption rate (OCR 
was driven by complex I substrates (pyruvate and malate). State III was induced by 
incubating mitochondria with ADP. State IV was induced by incubating mitochondria with 






Heme content may be reduced in CM-ABCB10-/- hearts 
In addition to measuring mitochondrial function, I also measured heme content in 
young WT flox/flox, WT Cre+, and CM-ABCB10 -/- hearts. At 3 months of age, presence 
of Cre does not appear to affect cardiac heme content. ABCB10 deletion in the cardiac 
myocyte reduced heme content by 19±12% (figure 4.11). This preliminary study indicates 
that ABCB10 deletion in the heart does reduce heme content, but more experiments are 
necessary to confirm this finding.  
 
Figure 4.11. ABCB10 deletion may reduce cardiac heme content. Heme content was 
measured in frozen LV samples from 3 month old WT F/F, WT Cre+, and CM-ABCB10 -
/- hearts via oxalic acid extraction. Heme content was unchanged in WT Cre+ mice. 






Differential gene expression in CM-ABCB10 -/- hearts 
My previous findings demonstrate that ABCB10 has a key role in regulating 
mitochondrial health. To determine the exact function of ABCB10 in the cardiac myocyte, 
the Boston University Microarray and Sequencing Resource Core Facility conducted a 
microarray analysis on RNA isolated from 3-month-old male WT Cre+ and CM-ABCB10 
-/- mice (n=3). First, the genotype of all the samples was confirmed by measuring the 
expression of ten probes targeting various sequences of the ABCB10 gene. All three CM-
ABCB10 -/- mice had lower expression of most of the probes, confirming that the excision 
strategy resulted in nonsense-mediated decay of the entire transcript. A principal 
component analysis showed that the samples separated mostly by genotype, which 
accounted for 24% of all variance in the samples (figure 4.12). A total of 1236 genes were 
changed between WT cre+ and CM-ABCB10 -/- mice with a threshold of p<0.05 (table 
4.1). False positives are common when evaluating large numbers of hypotheses. To limit 
false positives, a Benjamini-Hochberg false discovery rate correction was applied to 
generate FDR-corrected p values (q values). No individual genes were significantly 





Figure 4.12. Principal Component Analysis on mRNA isolated from WT Cre+ and 
CM-ABCB10 -/- hearts. Principal component analysis (PCA) performed across all genes 
in the array (20142 variables total). Grey circles represent WT Cre+ samples. Orange 
circles represent CM-ABCB10-/- samples. PC1 (genotype) accounted for the most 
variance in the data. Figure provided by the BU Microarray and Sequencing Resource Core 
Facility.  
In addition to the individual gene analysis, gene set enrichment analysis was 
conducted. Gene set enrichment analysis can identify sets of genes that are coordinately 
up-regulated or down-regulated in one of the groups.  504 gene sets were differentially 
regulated with an FDR q<0.25 (table 4.2). 374 of these gene sets were upregulated in CM-




downregulated biological process in CM-ABCB10-/- samples was mitochondrial 
translation (NES=-2.22, FDR q=0.0153). In addition, CM-ABCB10 -/- hearts 
downregulated components of the 90s pre-ribosome (NES=-2.17, FDR q=0.0110), RNA 
methylation (NES=-1.99, FDR q=0.0829), translation termination (NES=-1.99, FDR 
q=0.0732) and components of organellar ribosomes (NES=-1.94, FDR q=0.0690) (figure 
4.13). These data suggest that CM-ABCB10-/- hearts have impaired mitochondrial protein 
translation and likely impaired proteostasis. CM-ABCB10 -/- hearts also downregulated 
gene sets associated with mitochondrial matix (NES=-1.92, FDR q=0.0749), fatty acid 
metabolism (NES=-1.72, FDR q=0.1633), and the NAD metabolic process (NES=-1.88, 
FDR q=0.0891). These data indicate that deleting ABCB10 in the cardiac myocyte resulted 
in metabolic perturbations.  
 
p threshold Expected # of genes to change 
# of genes changed in WT Cre+ vs 
CM-ABCB10 -/- 
0.05 1007 1236 
0.01 201 231 
0.005 101 105 
0.001 20 8 
Table 4.1. Summary of differential gene expression. The total number of genes that 
were significantly altered in WT Cre+ vs CM-ABCB10 -/- compared the number of the 











Table 4.2. Summary of gene set enrichment analysis The total number of gene sets that 
were enriched in CM-ABCB10 -/- samples compared to WT cre+ controls at differing 






Figure 4.13. Most downregulated gene sets in CM-ABCB10 -/- hearts. A microarray 
analysis was conducted on mRNA isolated from 3-month-old WT Cre+ and CM-ABCB10 
-/- hearts. A) The most downregulated GO-Biological process labeled gene sets. B) The 
most downregulated GO-Cellular Component labeled gene sets. C) The most 




CM-ABCB10 samples upregulated a variety of gene sets associated with 
myocardial injury and regeneration (figure 4.14). The most upregulated gene set in CM-
ABCB10 samples was Hallmark-Hedgehog signaling (NES=2.23, FDR q=0.0120, figure 
4.14). Hedgehog signaling is upregulated in the ischemic heart and is thought to be 
cardioprotective 169–171. Two gene sets associated with development were also upregulated 
in CM-ABCB10 samples: GO-Nephric Duct Development (NES=2.12, FDR q=0.0405) 
and GO-Ventral Spinal Cord Interneuron Development (NES=2.09, FDR q=0.0523). The 
ventral spinal cord interneuron development gene set contains components of Hedgehog 
signaling, the Gli transcription factors, that modulate angiogenesis 172. The nephric duct 
development gene set contains genes associated with cardiac injury and regeneration, such 
as BMP4 173, ephrin/eph signaling 174,175, and components of Wnt signaling 176,177. 
Additionally, the hallmark Wnt beta catenin signaling gene set is upregulated in CM-
ABCB10 -/- samples (NES=1.98, FDR q=0.1037). Wnt signaling is essential for cardiac 
development and is re-activated after cardiac injury 177,178. Many of these gene sets appear 
to be a compensatory response, indicating that ABCB10 deletion caused some form of 
myocardial injury. It remains to be determined how or why these gene sets are activated in 
CM-ABCB10 -/- mice.  
In addition to upregulating regenerative pathways, CM-ABCB10 hearts also altered 
many gene sets associated with sodium and calcium handling. CM-ABCB10-/- hearts 
upregulated GO-calcium channel regulator activity (NES=1.85, FDR q=0.1599) and GO-
voltage gated calcium channel activity (NES=1.70, FDR q=0.1876). CM-ABCB10-/- 




previous study demonstrated that silencing ABCB10 can reduce protein levels of sodium-
calcium exchanger 49. Sodium and calcium are the predominant ions associated with 
cardiac conductance and contraction. If sodium or calcium homeostasis is altered in CM-






Figure 4.14. Most upregulated gene sets in CM-ABCB10 -/- hearts. A microarray 
analysis was conducted on mRNA isolated from 3 month old WT Cre+ and CM-ABCB10 
-/- hearts. A) The most upregulated GO-Biological process labeled gene sets. B) The most 





Transcription Factor Analysis 
The microarray analysis revealed that ABCB10 deletion may have impaired protein 
translation and proteostasis, indicating that ABCB10 may regulate a nuclear signal. To 
determine how deletion of a mitochondrial transporter could lead to changes in nuclear 
transcription, we conducted a transcription factor motif analysis of the microarray. The 
transcription factor motif analysis determines if genes with binding sites for specific 
transcription factors are coordinately upregulated or downregulated in CM-ABCB10 -/- 
samples. Genes upregulated in CM-ABCB10 -/- hearts were enriched with binding motifs 
for STAT5A (NES=1.88, FDR q=0.1596), ATF1 (NES=1.74, FDR q=0.1703), and NFKβ 
(NES=1.63, FDR q=0.2059), and CHOP (NES=1.55, FDR q=0.218) (figure 4.15). CHOP 
is a key mediator of the unfolded protein response and integrated stress response 178. 
Studies in striatal cells indicate that ABCB10 may regulate CHOP levels 85. However, CM-
ABCB10 -/- mice did not have altered CHOP or ATF4 levels (figure 4.16), indicating that 
ABCB10 deletion did not activate the integrated stress response. The enrichment of NF-
Kβ targets in CM-ABCB10-/- hearts is interesting, because ROS is a known regulator of 
NF-Kβ 179. The increase in genes with binding motifs for CHOP indicate that cardiac 
ABCB10 is necessary to maintain mitochondrial proteostasis and may play a role in the 





Figure 4.14. Transcription Factor Binding Motifs that were differentially regulated 
in CM-ABCB10 -/- hearts.  Transcription factor binding motif analysis was conducted on 
microarray data from 3-month-old WT Cre+ and CM-ABCB10 -/- hearts. Genes with 
binding sites for STAT5A_01 were the most enriched in CM-ABCB10 -/- hearts 
(NES=1.88, FDR q=0.1596).  
 
Figure 4.15. CHOP and ATF4 levels are not changed in CM-ABCB10 mice. Western 
blot analysis of CHOP and ATF4 levels in LV samples from 3-month-old WT Cre+ and 





In chapter 3, we showed that overexpression of ABCB10 can protect against 
oxidative challenge by increasing the cardiac myocytes antioxidant capacity. ABCB10 
overexpression increased cell survival and decreased cytosolic ROS after H2O2 challenge. 
Here, we show that deletion of cardiac myocyte ABCB10 leads to impaired mitochondrial 
function and early death in mice. Additionally, ABCB10 deletion led to differential gene 
changes indicative of impaired proteostasis. These observations suggest that ABCB10 is 
necessary to maintain mitochondrial function and cardiac survival under normal 
physiological conditions, possibly due to its antioxidant function or due to signaling related 
to ABCB10’s substrate.  
In vivo effects of ABCB10 knock-out in the cardiac myocytes 
While our in vitro studies demonstrate the potential of ABCB10 to exert an 
antioxidant effect, they do not establish the role of ABCB10 in normal expression levels. 
To test whether ABCB10 is functionally important in cardiac myocytes, we generated mice 
with a homozygous knock-out of ABCB10 restricted to the cardiac myocyte. At 4 months 
of age, at a time when there was no change in cardiac structure or resting function, there 
was an impairment in mitochondrial respiration and an increase in mitochondrial ROS 
generation. At 6 months of age CM-ABCB10 -/- mice began to die and more than 50% 
were dead by 10 months of age. This effect was not due to toxicity of the Cre promoter, 
since the first Cre+ mice did not die until 10 months of age.  
The exact cause of death in CM-ABCB10 -/- mice is unclear. αMHC Cre is known 




The increased ROS from ABCB10 deletion could have contributed to Cre-induced DNA 
damage, exacerbating the Cre toxicity and ultimately leading to early death. If this 
hypothesis was true, then CM-ABCB10 -/- mice should exhibit cardiac  dysfunction earlier 
than wild type cre+ mice. However, cardiac function declined at similar rates in wild type 
cre+ and CM-ABCB10 -/- mice. It is possible that the early death observed in CM-
ABCB10 -/- mice is caused by an early rapid decline in cardiac function that we missed 
with our serial echocardiography. It is also possible that ABCB10 deletion has impaired 
other cardiac functions, such as conductance, leading to sudden death. Multiple calcium 
and sodium handling proteins can be oxidatively modified 180 and these oxidative 
modifications can lead to the development of arrhythmias 181. Furthermore, our microarray 
analysis indicates that genes associated sodium ion homeostasis, voltage gated calcium 
channels, and calcium channel regulators are altered. If sodium or calcium homeostasis is 
altered in CM-ABCB10-/- hearts, either by oxidative modification or changes in protein 
level, then it is possible CM-ABCB10-/- could develop an arrhythmia or electrical 
disturbance, leading to sudden death. Electrical studies would have to be conducted on 
CM-ABCB10 -/- hearts to determine if they have impaired conductance. These findings 
demonstrate that cardiac ABCB10 is necessary for survival, but the mechanism remains to 
be determined. 
ABCB10 affects cardiac proteostasis 
Our microarray analysis indicates that cardiac deletion of ABCB10 impairs 
translation of mitochondrial proteins, but does not increase levels of CHOP or ATF4. These 




ABCB10 deletion did not lead to activation of the unfolded protein response. Previous 
studies have shown that ABCB10 may regulate the unfolded protein response in 
mitochondria. Yano saw that ABCB10 depletion in a liver cell line led to impaired 
mitochondrial UPR response, as evidenced by reduced levels of key mitochondrial 
chaperones 82. Another study, in mouse striatal cells, found that ABCB10 depletion led to 
a decrease in both CHOP level and mtUPR gene levels 85.  They also showed that 
overexpressing ABCB10 could restore the levels of both CHOP and mtUPR genes 75. Our 
findings here are consistent with the hypothesis that ABCB10 regulates mitochondrial 
proteostasis; however, our data contrasts with the conclusion that ABCB10 regulates 
CHOP. Genes with CHOP binding motifs were slightly upregulated in CM-ABCB10 -/- 
hearts, but CHOP levels were unaffected by ABCB10 deletion. Our studies were conducted 
in mouse heart, while the other study was conducted in striatal cells. The difference in 
tissue type may explain our discrepancies. We measured CHOP levels basally in young 
CM-ABCB10 -/- hearts, when they have mitochondrial dysfunction, but prior to Cre 
toxicity and mortality. It is also possible that ABCB10 deletion impairs the cells ability to 
upregulate CHOP when necessary, impairing cells ability to respond to proteostatic stress.  
There are two explanations for why ABCB10 deletion reduced transcript levels of 
genes associated with mitochondrial protein translation. One is that ABCB10 either exports 
or stabilizes a nuclear signaling molecule that regulates the mitochondrial unfolded protein 
response. If this hypothesis is true, then CM-ABCB10 -/- should be incapable of activating 
the mtUPR in response to stress. Another explanation is that ABCB10 deletion damaged 




substrate, and that the damaged mitochondria activated a signaling cascade which 
repressed transcription and translation. If this hypothesis is true, we should see signs of 
mitochondrial damage basally. Taken together, these data demonstrate that ABCB10 has a 
key role in regulating mtUPR, although whether ABCB10 regulates mtUPR through a 
signaling cascade or merely as a consequence of regulating mitochondrial function remains 
to be determined.  
ABCB10 differential gene expression 
 Deletion of ABCB10 in the cardiac myocyte led to vast transcriptional changes in 
the heart. There are two major trends in the microarray data. First, ABCB10 deletion 
reduced genes associated with mitochondrial proteins transcription and translation, 
including many components of mitochondrial ribosomes Second, lack of ABCB10 induced 
upregulation of many cardioprotective pathways, including Wnt and Hedgehog signaling. 
In the previous section, I covered the link between ABCB10 and regulation of proteostasis. 
Here, I will discuss the implications of ABCB10 affecting hedgehog and Wnt signaling.  
 Both Wnt and Hedgehog signaling play essential roles in cardiac and vascular 
development 182–185 and both pathways are re-activated during cardiac injury 176,177,186–188. 
However, it is controversial if activation of these pathways is cardioprotective. 
Upregulation of the hedgehog pathway, by sonic hedgehog administration, in cardiac 
myocytes and fibroblasts protected the heart against both acute and chronic myocardial 
ischemia, preserving cardiac function, improving neovascularization, decreasing fibrosis, 
and apoptosis 182. Administration of a sonic hedgehog pathway agonist improved cardiac 




inhibiting the hedgehog pathway improved cardiac dilation and function after myocardial 
ischemia and reperfusion 170. These studies, with their contradictory findings, indicate that 
the hedgehog signaling pathway has a complex role in regulating cardiac injury response 
that may be vary depending on the method of activation, time of administration, and the 
level of activation achieved.  
 Wnt signaling is upregulated after myocardial infarction 188,189 and inhibition of 
Wnt signaling, through overexpression of an antagonist, decreased myocardial infarct size 
190. Another study, in a model of acute ischemic cardiac injury, showed that Wnt signaling 
is activated, specifically in the injured regions of the heart, and that Wnt signaling is pro-
fibrotic 191. Surprisingly, disrupting Wnt signaling severely impaired cardiac function after 
injury, indicating that this pro-fibrotic response may be necessary to maintain cardiac 
function after acute ischemic injury 191. Small molecule Wnt inhibitors have been shown 
to attenuate cardiac remodeling, fibrosis, and improve cardiac function after myocardial 
infarction 192–195. Taken together, ABCB10 deletion has led to upregulation of injury 
response pathways, with both adaptive and maladaptive potential. It is possible that 
ABCB10 deletion has induced a form of ischemia or cell death, possibly due to decreased 
mitochondrial function, and the cardiac myocyte has activated regenerative pathways in an 
attempt to compensate. It is also possible that ABCB10’s export function relays a signal of 
mitochondrial health to the nucleus and the rest of the cell.  
 CONCLUSIONS 
In this chapter, we demonstrated that cardiac ABCB10 is necessary for survival and 




evidence that ABCB10 is necessary to maintain normal protein translation within the 
mitochondria. These findings are supported by our previous chapter, which showed that 
increasing ABCB10 levels can protect the cardiac myocyte against ROS-induced cell death 
and increase the cells’ antioxidant capacity. This study, and our prior study in mice with 
heterozygous global knockout of ABCB10, show that this mitochondrial transporter plays 
an important role in the heart by protecting cardiac myocytes, potentially by regulating 
oxidative stress, proteostasis, and possibly electrical stability.  
Targeting antioxidants to the mitochondria through pharmacological interventions 
or transgenic approaches can protect against myocardial dysfunction and failure in a variety 
of pathological conditions 18,36,37,39,196. Identification of the antioxidant role of ABCB10 in 
the cardiac myocyte provides a new potential therapeutic target for the therapy of 












Figure A.1. Heatmap for GO-Mitochondrial Translation biological process gene set. 
The three columns on the left with the grey header (WT-2, WT-3, and WT-4) represent 
WT Cre+ samples. The three columns on the right with the orange header (ABC-5, ABC-
6, and ABC-7) represent CM-ABCB10 -/- samples. NES=-2.22, FDR q=0.0153. Heatmap 





Figure A.2. Heatmap for GO-Glyoxylate Metabolic Process biological process gene 
set. The three columns on the left with the grey header (WT-2, WT-3, and WT-4) 
represent WT Cre+ samples. The three columns on the right with the orange header 
(ABC-5, ABC-6, and ABC-7) represent CM-ABCB10 -/- samples. NES=-2.18, FDR 






Figure A.3. Heatmap for GO-90S Preribosome cellular component gene set. The three 
columns on the left with the grey header (WT-2, WT-3, and WT-4) represent WT Cre+ 
samples. The three columns on the right with the orange header (ABC-5, ABC-6, and ABC-
7) represent CM-ABCB10 -/- samples. NES=-2.17, FDR q=0.0110. Heatmap provided by 





Figure A.4. Heatmap for GO-Intra Golgi Vesicle Mediated Transport biological 
process gene set. The three columns on the left with the grey header (WT-2, WT-3, and 
WT-4) represent WT Cre+ samples. The three columns on the right with the orange header 
(ABC-5, ABC-6, and ABC-7) represent CM-ABCB10 -/- samples. NES=-2.09, FDR 





Figure A.5. Heatmap for GO-Translational Termination biological process gene set. 
The three columns on the left with the grey header (WT-2, WT-3, and WT-4) represent 
WT Cre+ samples. The three columns on the right with the orange header (ABC-5, ABC-
6, and ABC-7) represent CM-ABCB10 -/- samples. NES=-1.99, FDR q=0.0732. Heatmap 





Figure A.6. Heatmap for GO-Organellar Ribosome cellular component gene set. The 
three columns on the left with the grey header (WT-2, WT-3, and WT-4) represent WT 
Cre+ samples. The three columns on the right with the orange header (ABC-5, ABC-6, and 
ABC-7) represent CM-ABCB10 -/- samples. NES=-1.94, FDR q=0.0690. Heatmap 





Figure A.7. Heatmap for GO Mitochondrial Matrix gene set. The three columns on the 
left with the grey header (WT-2, WT-3, and WT-4) represent WT Cre+ samples. The three 
columns on the right with the orange header (ABC-5, ABC-6, and ABC-7) represent CM-
ABCB10 -/- samples. NES=-1.92, FDR q=0.0749. Heatmap provided by BU Microarray 





Figure A.8. Heatmap for GO NAD metabolic process gene set. The three columns on 
the left with the grey header (WT-2, WT-3, and WT-4) represent WT Cre+ samples. The 
three columns on the right with the orange header (ABC-5, ABC-6, and ABC-7) represent 
CM-ABCB10 -/- samples. NES=-1.88, FDR q=0.0891. Heatmap provided by BU 





Figure A.9. Heatmap for Hallmark Fatty Acid Metabolism gene set. The three columns 
on the left with the grey header (WT-2, WT-3, and WT-4) represent WT Cre+ samples. 
The three columns on the right with the orange header (ABC-5, ABC-6, and ABC-7) 
represent CM-ABCB10 -/- samples. NES=-1.72, FDR q=0.1633. Heatmap provided by BU 





Figure A.10. Heatmap for Hallmark Hedgehog Signaling pathway gene set. The three 
columns on the left with the grey header (WT-2, WT-3, and WT-4) represent WT Cre+ 
samples. The three columns on the right with the orange header (ABC-5, ABC-6, and ABC-
7) represent CM-ABCB10 -/- samples. NES=2.23, FDR q=0.0120. Heatmap provided by 







Figure A.11. Heatmap for GO-Nephric Duct Development biological process gene set. 
The three columns on the left with the grey header (WT-2, WT-3, and WT-4) represent 
WT Cre+ samples. The three columns on the right with the orange header (ABC-5, ABC-
6, and ABC-7) represent CM-ABCB10 -/- samples. NES=2.12, FDR q=0.0405. Heatmap 






Figure A.12. Heatmap for GO-Ventral Spinal Cord Interneuron Development 
biological process gene set. The three columns on the left with the grey header (WT-2, 
WT-3, and WT-4) represent WT Cre+ samples. The three columns on the right with the 
orange header (ABC-5, ABC-6, and ABC-7) represent CM-ABCB10 -/- samples. 
NES=2.09, FDR q=0.0523. Heatmap provided by BU Microarray and Sequencing 






Figure A.13. Heatmap for Hallmark Wnt Beta Catenin Signaling gene set. The three 
columns on the left with the grey header (WT-2, WT-3, and WT-4) represent WT Cre+ 
samples. The three columns on the right with the orange header (ABC-5, ABC-6, and ABC-
7) represent CM-ABCB10 -/- samples. NES=1.98, FDR q=0.1037. Heatmap provided by 






Figure A.14. Heatmap for GO Calcium Channel Regulator Activity gene set. The three 
columns on the left with the grey header (WT-2, WT-3, and WT-4) represent WT Cre+ 
samples. The three columns on the right with the orange header (ABC-5, ABC-6, and ABC-
7) represent CM-ABCB10 -/- samples. NES=1.85, FDR q=0.1599. Heatmap provided by 





Figure A.15. Heatmap for GO Voltage Gated Calcium Channel Activity gene set. The 
three columns on the left with the grey header (WT-2, WT-3, and WT-4) represent WT 
Cre+ samples. The three columns on the right with the orange header (ABC-5, ABC-6, and 
ABC-7) represent CM-ABCB10 -/- samples. NES=1.70, FDR q=0.1876. Heatmap 






Figure A.16. Heatmap for GO Sodium ion homeostasis gene set. The three columns on 
the left with the grey header (WT-2, WT-3, and WT-4) represent WT Cre+ samples. The 
three columns on the right with the orange header (ABC-5, ABC-6, and ABC-7) represent 
CM-ABCB10 -/- samples. NES=-1.65, FDR q=0.2159. Heatmap provided by BU 
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175.       Gessert S, Kühl M. The Multiple Phases and Faces of Wnt Signaling During 
Cardiac Differentiation and Development. Circulation Research [Internet]. 2010 
[cited 2020 Mar 7];107:186–199. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20651295 
176.       Foulquier S, Daskalopoulos EP, Lluri G, Hermans KCM, Deb A, Blankesteijn 
WM. WNT Signaling in Cardiac and Vascular Disease. Pharmacological reviews 
[Internet]. 2018 [cited 2020 Mar 7];70:68–141. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29247129 
177.       Ozhan G, Weidinger G. Wnt/β-catenin signaling in heart regeneration. Cell 
regeneration (London, England) [Internet]. 2015 [cited 2020 Mar 7];4:3. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/26157574 
178.       Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM, 
Pakos‐Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The 
integrated stress response. EMBO reports [Internet]. 2016 [cited 2019 Dec 
8];17:1374–1395. Available from: 
https://onlinelibrary.wiley.com/doi/abs/10.15252/embr.201642195 
179.       Lingappan K. NF-κB in oxidative stress. Current Opinion in Toxicology 
[Internet]. 2018 [cited 2019 Dec 18];7:81–86. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29862377 
180.       Wagner S, Rokita AG, Anderson ME, Maier LS. Redox Regulation of Sodium 
and Calcium Handling. Antioxidants & Redox Signaling [Internet]. 2013 [cited 
2020 Mar 8];18:1063–1077. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/22900788 
181.       Akar FG, Aon MA, Tomaselli GF, O’Rourke B. The mitochondrial origin of 
postischemic arrhythmias. Journal of Clinical Investigation [Internet]. 2005 [cited 
2020 Mar 8];115:3527–3535. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16284648 
182.       Kusano KF, Pola R, Murayama T, Curry C, Kawamoto A, Iwakura A, Shintani 
S, Ii M, Asai J, Tkebuchava T, Thorne T, Takenaka H, Aikawa R, Goukassian D, 
von Samson P, Hamada H, Yoon Y, Silver M, Eaton E, Ma H, Heyd L, Kearney 
M, Munger W, Porter JA, Kishore R, Losordo DW. Sonic hedgehog myocardial 




Nature Medicine [Internet]. 2005 [cited 2020 Mar 7];11:1197–1204. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/16244652 
183.       Dyer LA, Makadia FA, Scott A, Pegram K, Hutson MR, Kirby ML. BMP 
signaling modulates hedgehog-induced secondary heart field proliferation. 
Developmental Biology [Internet]. 2010 [cited 2020 Mar 7];348:167–176. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20920499 
184.       Lavine KJ, White AC, Park C, Smith CS, Choi K, Long F, Hui C, Ornitz DM. 
Fibroblast growth factor signals regulate a wave of Hedgehog activation that is 
essential for coronary vascular development. Genes & Development [Internet]. 
2006 [cited 2020 Mar 7];20:1651–1666. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16778080 
185.       Tian Y, Cohen ED, Morrisey EE. The importance of Wnt signaling in 
cardiovascular development. Pediatric cardiology [Internet]. 2010 [cited 2020 Mar 
7];31:342–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19967349 
186.       Pahnke A, Conant G, Huyer LD, Zhao Y, Feric N, Radisic M. The role of Wnt 
regulation in heart development, cardiac repair and disease: A tissue engineering 
perspective. Biochemical and biophysical research communications [Internet]. 
2016 [cited 2020 Mar 7];473:698–703. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26626076 
187.       Dunaeva M, Waltenberger J. Hh signaling in regeneration of the ischemic heart. 
Cellular and molecular life sciences : CMLS [Internet]. 2017 [cited 2020 Mar 
7];74:3481–3490. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28523343 
188.       Oerlemans MIFJ, Goumans M-J, Middelaar B, Clevers H, Doevendans PA, 
Sluijter JPG. Active Wnt signaling in response to cardiac injury. Basic Research in 
Cardiology [Internet]. 2010 [cited 2020 Mar 7];105:631–641. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20373104 
189.       Aisagbonhi O, Rai M, Ryzhov S, Atria N, Feoktistov I, Hatzopoulos AK. 
Experimental myocardial infarction triggers canonical Wnt signaling and 
endothelial-to-mesenchymal transition. Disease Models & Mechanisms [Internet]. 
2011 [cited 2020 Mar 7];4:469–483. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21324930 
190.       Barandon L, Couffinhal T, Ezan J, Dufourcq P, Costet P, Alzieu P, Leroux L, 
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